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CHAPTER 1: SUMMARY OF IRON SULFUR CLUSTERS, THE
MOLECULAR BASIS OF FRIEDREICH’S ATAXIA AND DISEASE
TREATMENT STRATEGIES
1.0

Prelude
Iron sulfur cluster are a remarkable cofactor spanning across all species,

performing simple and complex functions essential for life. During my time as a graduate
student in the Stemmler lab, my appreciation for these cofactors grew along with me.
Most of my work focuses on the scaffold protein, Isu1, in the Iron Sulfur Cluster Complex
(ISC) in Saccharomyces cerevisiae. In this chapter, I will highlight a few of the many
types of Fe-S clusters and the diverse roles they hold across biology. The purpose for
reviewing the types and functions of Fe-S clusters is in their significance to the disease
state, Friedreich’s Ataxia. This disease is the result of a breakdown in the ISC pathway
and changes in cluster assembly will therefore affect multiple systems. Related to Fe-S
cluster assembly, this chapter contains a detailed description about the clinical
presentation and molecular pathogenesis of Friedreich’s Ataxia (FA). Keeping all this in
mind and with our new location in the Department of Pharmaceutical Sciences I found it
important to review all current and past clinical trials related to FA. Understanding the
pitfalls of current therapies provides context and significance to our work as we aim to
identify new therapeutic targets by developing an accurate model for Fe-S cluster
assembly.

1.1 Introduction
Iron sulfur clusters are remarkable cofactors utilized widely in biology to perform
critical biological reactions. The goal of this chapter is to summarize what is known about
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cellular Fe-S cluster synthesis, highlight common Fe-S cluster types and outline the
function of these essential cofactors within cells. Understanding cluster assembly and
function is significant for advancing treatment strategies for Friedreich’s Ataxia (FA)
patients. Current treatments focus on symptom management or to reduce cellular
damage by using antioxidants or chelation therapy, but none of these directives are
curative. Clinical trials are in process for drugs aimed at increasing frataxin expression.
New therapies targeting cluster assembly could also be considered and a detailed model
for Fe-S assembly is therefore required. This work focuses on how the yeast Fe-S cluster
scaffold protein, Isu1, functions as a part of cluster assembly. For clarity, a comparison
of nomenclature across species is listed in table 1.1.

1.2 Types of clusters and their function
Fe-S clusters were discovered in the 1960s as a catalytic center for electron
transfer. 1, 2 They are an ancient cofactor and perhaps one of the first biocatalysts. Since
their discovery, they have appeared in all forms of life ranging from bacteria to higher
eukaryotes, and an understanding of their cellular roles have significantly expanded.1
Initially suggested to only perform catalysis and electron transfer reactions, Fe-S clusters
are now known to impact protein structure and gene regulation. 2, 3, 4 Fe-S clusters exist
in flat or caged-like structures ranging from the rubredoxin family of 1Fe-4S to the 8Fe7S cluster, and they also exist as a heteronuclear metal cluster.1 Commonly found in
biology are 2Fe-2S, 3Fe-4S and 4Fe-4S clusters. Rubredoxin clusters contain iron
bridged by protein cysteine residues, also known as a 1Fe-4S cluster. Larger cluster
sizes adopt a diamond or cuboidal shape. 2Fe-2S clusters have

3
Yeast

Human

Bacterial

Isu1

ISCU

IscU

Yfh

FXN

CyaY

Nfs1

NFS1

IscS

Isd11

ISD11

----

Acp1

ACP

ACP(ec)

Yah1

FDX

Fdx

Table 1.1 Comparison of yeast, human and bacterial ISC nomenclature. Proteins
described in this report are all from yeast proteins (left column) and literature comparisons
are made for both human and bacterial orthologs. Nomenclature is described above for
clarity.
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a diamond shape compared to 4Fe-4S clusters with a cuboidal geometry. The
architecture of the cluster drives function of the partner protein. Shared among Fe-S
cluster types are iron ions bridged by sulfide ligated to proteins by cysteine residues.
However, other ligating residues such histidine, aspartate and glutamate are observed
and are necessary to modulate redox potential and activity of the cluster.5,6 In this section,
we will compare these common cluster types and show the diverse roles they play in
regulating their partner protein’s function.
The role of Fe-S clusters has significantly expanded since their initial discovery as
participating in electron transfer reactions. A classic example of the role of Fe-S clusters
is in the electron transport chain. Multiple clusters are present in Complexes I,II and III of
the ETC7 and provide electron shuttling function for ATP production. Eukaryotic Complex
I contains eight Fe-S clusters and Complex II contains three Fe-S clusters.7 In each case,
electrons are shuttled from cluster to cluster generating a proton gradient that is required
for ATP production.8 Fe-S clusters are also noted for their involvement in metabolic
catalysis. One such example of cluster related catalysis is the conversion of citrate to
isocitrate by the protein aconitase.9 The aconitase cluster is directly involved in the
reaction and when damaged, the role of the protein changes. Aconitase has a metabolic
catalysis function when a 4Fe-4S cluster is bound.9 However, when the protein lacks its
cluster, it is known as the iron regulatory protein which is involved in cellular iron
sensing.10 More recently, new roles for Fe-S clusters have emerged. Fe-S Clusters are
now found in proteins that mediate DNA transcription, regulate DNA repair mechanisms
and modify protein folding. Regulation of DNA transcription is achieved by exchanging
of the Fe-S redox state in the SoxR protein. The transcriptional function of the SoxR
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protein is activated by oxidation of the 4Fe-4S cluster.3 Clusters play a role in DNA repair
by regulating base excision (EndoIII) or by repairing mismatches (MutY).4 The cluster
does not play a structural role but instead modulates redox activity.4 There are instances
where an Fe-S cluster plays a structural role that drives protein folding. Bacterial
ferredoxin, for instance, has been shown to adopt a more stable/active conformation
when the cluster is bound.11 Fe-S clusters are critical in biology for driving reactions for
catalysis, gene regulation and protein folding. Should cluster synthesis become impaired,
the effects would be widespread.
1.2.1 Examples of mononuclear Fe-S Clusters in biology
Mononuclear Fe-S clusters are typically found as rubredoxins in prokaryotes. Their
role, although somewhat obscure, is catalysis/electron transfer, structural or to prevent
oxidative stress. Rubredoxin motifs are found in about 74,000 proteins.12 Since they
contain one iron ion, their structure is ideal for one electron transfer reactions such as in
the C. pasteurianum rubredoxin.13 However, rubredoxins also can play a structural role
14

, Mukhopadhyay) or prevent protein damage from oxidative stress.15 More recently,

rubredoxins are thought to provide Fe for catalysis such as in case of enzyme iron
depletion.12 For example, 3-Hydroxyanthranilate 3,4-dioxygenase (HAO) is a non-heme,
iron dependent protein which activates oxygen for oxidative cleavage.16

Unique to

bacterial HAO is a nearby second iron site which is rubredoxin like.12,17 This site is shown
to be a “spare tire” to replenish iron for catalysis where the rubredoxin center is an
accessory to nearby catalytic center. Rubredoxin like centers have also been found to
play a role in iron by hepcidin and may be involved in the interaction between hepcidin
and ferroportin.18 The cluster center likely causes a conformation change resulting in the
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maturation of the peptide. The multiple and diverse roles that rubredoxin clusters can
play in biology demonstrates that clusters can have a large impact on catalysis, structure
and iron regulation.
1.2.2 Examples of 2Fe-2S clusters in biology.
The 2Fe-2S cluster is the most common cluster type and assembly takes place in
the mitochondria in Eukaryotes. This cluster type is found ubiquitously and performs a
wide range of functions. These roles include electron transfer reactions for metabolism,
transcriptional regulation, regulation of mitochondrial iron homeostasis, regulation of RNA
and oxygen sensing. A quintessential function of Fe-S clusters is electron transfer.
Electron transfer reactions by 2Fe-2S clusters are evident in the electron transport chain
in Complex I, II and III.19 Specific arrangement of reduction potentials by clusters allows
for electron shuttling required for reduction of O2 to H2O.20 2Fe-2S clusters also play a
role in bacterial transcriptional regulation of DNA by proteins including SoxR.

The

variable redox state of the 2Fe-2S cluster within SoxR plays a role in modulating
transcriptional activity in response to oxidative stress.21 2Fe-2S clusters can also play a
role in iron and metabolic sensing. For instance, a large family of 2Fe-2S cluster proteins,
called mitoNEETs, are found in the outer mitochondrial membrane and regulate
mitochondrial iron homeostasis.22

Unique to the mitoNEET family is the 3Cys/1His

coordination of the cluster, this site on the protein was originally thought to be a Zn finger
site.22 MitoNEET is located in the outer mitochondrial membrane and is thought to
facilitate mitochondrial Fe-S transport for cytosolic cluster assembly.23

Ob/Ob mice

models show mitoNEET regulates iron homeostasis through mitochondrial Fe transport.24
Pioglitazone, a pharmacological agent for type 2 diabetes, targets mitoNEET suggesting
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an important role for iron and cluster trafficking in metabolic disease.23 A role for 2Fe-2S
clusters providing regulation of RNA can be demonstrated by the CPSF30 protein.
CPSF30 is a 2Fe-2S cluster protein where the cluster is bound at a zinc-finger like site,
similar to mitoNEET. CPSF30 contains an Fe-S site and Zn sites which are both required
for RNA binding.25

Oxygen sensing functions are another role for a 2Fe-2S cluster.

Fumarate and Nitrate Reduction or FNR serves as a “master switch” in bacteria for
switching between anaerobic and aerobic respiration.

The sensing function is

accomplished by a 4Fe-4S cluster. Under oxygen exposure, the cluster is degraded to a
2Fe-2S cluster, inhibiting dimerization of the protein which consequently is unable to bind
DNA.26 Not only does the cluster type provide a sensing function but it drives the protein’s
fold to regulate transcription. The 2Fe-2S cluster serves many roles in biology, including
DNA activation, oxygen sensing for metabolism and mitochondrial iron homeostasis.
These are a few of many 2Fe-2S cluster proteins which demonstrate the diverse and
essential nature of clusters.
1.2.3 Examples of 4Fe-4S clusters in biology
Similar to the 2Fe-2S cluster, there are 4Fe-4S cluster proteins involved in
metabolic catalysis, oxygen, radical and iron sensing. Hydrogenases are a large family
of 4Fe-4S proteins involved in metabolic catalysis of dihydrogen 27 consisting of NiFe and
FeFe hydrogenases. Hydrogenases contain a distal and proximal 4Fe-4S cluster and a
mesial 4Fe-3S cluster.27 These clusters are buried within the protein and therefore
provide an electron transfer function between metal centers and the protein surface.27
Another class of 4Fe-4S cluster proteins are the radical SAM enzymes, containing over
600 members.28 Radical SAM enzymes utilize a 4Fe-4S cluster to facilitate an electron
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transfer step for cleavage of unreactive C-H bonds.28 Initiator of the reaction is sadenosyl-methionine or SAM. Cleavage of SAM results in a 5-deoxyadenosyl 5’-radical
which serves as an intermediate for these proteins. More recently however, 4Fe-4S
clusters have been implicated in DNA repair for their ability to regulate protein
conformation and facilitate charger transfer.29 EndoIII for example, contains a 4Fe-4S
cluster. Originally thought to play a role in maintaining structure because it was insensitive
to redox events, recent evidence suggests these proteins do in fact have a redox ability.4,
30

MutY is another endonuclease containing a 4Fe-4S cluster and it repairs oxo G:A

mismatches.30 Oxygen sensing abilities of 4Fe-4S clusters is demonstrated by FNR, as
discussed previously. In this case, the cluster is responsible for managing the sensitivity
of the transcription factor to oxygen. During anaerobic conditions, FNR is expressed. The
functional protein is found as a dimer with an intact 4Fe-4S cluster and binds to DNA for
expression of anaerobic proteins. The protein is inactivated when the 4Fe-4S cluster is
degraded upon exposure to oxygen. This results in a monomeric/inactive protein which
cannot bind DNA for transcription of anaerobic proteins.31 Similar to FNR is the role of
Aconitase to iron regulation which is driven by the state of the 4Fe-4S cluster. When the
4Fe-4S cluster is bound, aconitase performs an essential metabolic function, catalyzing
citrate to isocitrate.10,

32

When the cluster is degraded due to anemic conditions,

aconitase plays a role in iron regulation by downregulating ferritin expression.33
Aconitase, without its 4Fe-4S cluster, is therefore known as iron regulatory protein
(IRP).32.
1.2.4 Examples of 3Fe-4S clusters in biology
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While rubredoxins, 2Fe-2S and 4Fe-4S cluster types make up the largest groups
of Fe-S containing proteins, 3Fe-4S clusters are utilized for electron transfer and iron
regulation. Often, these clusters are a product of degradation from a 4Fe-4S cluster for
sensing, but they are also fine-tuned clusters to accommodate specific activity. As
discussed previously, aconitase contains a 4Fe-4S protein which is degraded to a 2Fe2S cluster. Along the way, however, is the presence of a 3Fe-4S cluster intermediate.
This is seen via the H2O2 initiated disassembly.34 A more obvious role of the 3Fe-4S
cluster is evident in bacterial arsenite oxidase. The unique 3Fe-4S clusters of this protein
acts as a one electron acceptor. It facilitates electron transfer from the Mo containing
active site to the nearby 2Fe-2S Riekse center then to physiological electron acceptor.35
A 3Fe-4S cluster is also found in a t-RNA modification enzyme, Ncs6.36 This specific
cluster is required for sulfur transfer and is found in both archaea and eukaryotes,
suggesting a possible evolutionary pathway for cluster utilization across species.36
Hydrogenases, discussed above, contains two 4Fe-4S clusters and an additional 3Fe-4S
cluster. This 3Fe-4S cluster is in close proximity to a low potential 4Fe-4S cluster which
allows for either an electron transfer reaction or protein stabilization function.27, 37
1.2.5 Examples of multinuclear Fe-S clusters in biology
The most complex member of the Fe-S cluster family is the multinuclear cluster.
Utilization of other metal species can alter redox potential in a way to accommodate a
specific function. Nitrogenases, involved in the reduction of dinitrogen, for instance
contain two multinuclear sites known as FeMoCo and FeVCo.38 The FeMo cofactor is
proposed to improve cluster stability during turnover whereas the FeV cofactor is slightly
less favorable.38 These large and complex cluster types make them challenging for
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spectroscopic studies, but they are able to achieve elaborate reactions in biology.39
Overall, much work is needed to investigate these cluster types to have a complete
understanding of their function.40

1.3 Mitochondrial Fe-S Cluster synthesis
This report focuses on molecular interactions essential for eukaryotic Fe-S cluster
biosynthesis. While Fe-S clusters have been studied for decades, questions regarding
their synthesis remain unanswered. Cluster synthesis in eukaryotes primarily takes place
in the mitochondria, with an additional synthesis pathway in the cytosol.41 Eukaryotic
cluster synthesis of a 2Fe-2S cluster is achieved by the iron sulfur cluster (ISC) machinery
(Figure 1.1). Cluster synthesis is central to the scaffold protein: “ISCU” in humans, Isu1
in yeast. A cysteine desulfurase enzyme, NFS or Nfs1, and its accessory protein, ISD11
or Isd11 transfer persufide to ISCU. The production of persulfide occurs on the active site
cysteine residue in the flexible loop of Nfs.42, 43 It is possible that this flexible loop is the
interface of Nfs to ISCU.42

The delivery of iron for cluster assembly has been long

debated however our lab hypothesizes that frataxin (FXN) binds ferrous iron in vitro and
associate with ISCU under these conditions.44, 45 Other reports suggest that frataxin is the
source of iron for cluster assembly but only binds to ISCU during ISC complex
association.46 Others suggest that frataxin is an allosteric regulator of Nfs-Isd11.47, 48 In
order for cluster synthesis to occur, a source of reducing equivalents needs to be
provided. Ferredoxin provides reducing equivalents for cluster formation and is thought
to bind at the same ISCU interface as frataxin.46 Recent reports have now shown a new
protein, Acyl carrier 1 protein or ACP1, associated with the ISC complex.42, 49 ACP1
interacts with Isd11 and has been shown to be critical for cluster formation however little
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is known about its overall contribution to cluster assembly.49 This report focuses on FeS cluster assembly in Saccromyces cerevisiae and therefore will use nomenclature
specific to yeast orthologs (ISCU-Isu1, FXN-Yfh). While there are several structural
reports on the ISC complex

42, 43, 49, 50

questions remain unanswered about key cluster

assembly events, especially related to Isu1.
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Figure 1.1 . Iron sulfur cluster (ISC) assembly complex model. Cysteine desulfurase
(green) and its accessory, Isd11 (yellow) with Acp1 (pink). ISCU (blue) is Zn bound and
shown in complex with frataxin (red). Nfs-Isd11, Acp1, ISCU and frataxin are referred to
as the NIAUF complex. Adapted from PDB 6ZNU.
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1.3.1 Summary of the yeast scaffold protein, Isu1
The scaffold protein, Isu1, is a dynamic protein central to cluster assembly. The
active site of Isu1 contains 3 cystine residues and 1 histidine residue used to produce the
Fe-S cluster.42 Isu1 orthologs have been shown to exist in multiple conformations (Figure
1.2); disordered and structured.51,

52

Key differences between the structured and

disordered state lie within the protein’s C-terminal region.43 When the protein becomes
disordered, the secondary structure is lost, leading to a flexible loop region.

The

fluctuation between these states is necessary to accommodate interactions with protein
partners used for delivery of iron and persulfide, and for cluster transfer. The structured
state is stabilized upon cluster formation to the active site. The disordered state has been
shown to preferentially bind the cysteine desulfurase.53 There is little evidence to suggest
which state of Isu1 interacts with frataxin, but residues found on frataxin’s b-sheets 1, 2
and 3 are purposed to interact with the LPPVK residues on the loop region of Isu1 on the
N-terminal side of the protein’s active site (Figure 1.3).43, 50
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Figure 1.2 Structured and disordered conformation of Isu1. The structured state of
Isu1 is stabilized upon cluster or Zn binding to the active site. The disordered state is
favored when the active site is unbound and the C-terminal helix (yellow) becomes less
helical near the active site.
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Figure 1.3 Active site of ISCU in relation to Nfs and frataxin. ISCU (blue) is Zn bound
(yellow sphere) and shown in complex with frataxin (red). LPPVK region of ISCU
(magenta) interacts with sheet 1, 2 and 3 of frataxin. Cysteine 381 (black) of Nfs (green)
transfers persulfide to the C69, C95, C138, H137 active site (orange) of ISCU. Adapted
from PDB 6ZNU.
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1.3.2 Unanswered questions for Isu1 in cluster assembly.
Although the ISC complex has been extensively studied, there are still unanswered
questions about the dynamic nature of Isu1. Events detailing iron binding and transfer
remain controversial. This report and others suggest that iron binds to a distinct site
separate from the active site.54, 55 Events detailing with how iron enters the active site
remain unclear, but it is likely to be protein facilitated. While the iron binding site is likely
not the active site, the exact residues coordinating iron before active site transfer are
elusive. Events for substrate transfer and ISC interactions are further complicated by the
Isu1’s ability to bind Zn. Previous reports have shown that Isu binds Zn in vitro and
without treatment with EDTA, Zn will remain bound.42, 56 Multiple reports have shown that
Zn binding to Isu1 orthologs increases the protein’s stability, alters its structure, impacts
its cluster assembly activity and alter its dimerization properties.43, 56, 57 Recent findings
in vivo suggest under high Zn conditions, the bacterial scaffold binds Zn in the active site
diminishing cluster assembly activity.58 In addition, the contribution of the C-terminal
region has been largely unexplored in relation to cluster assembly despite its significance
to ISU myopathy. It has been reported that the C-terminus of human ISCU is prematurely
truncated and contains a mutation of 20 residues.59 A current and unconfirmed hypothesis
is that these changes may impair dimerization or stability.60 This work focuses on
addressing these questions to add to our working model of Fe-S cluster assembly.
Ultimately these findings can help design more accurate therapeutics in the treatment of
Friedreich’s Ataxia.

1.4 Friedreich’s Ataxia and current treatment strategies
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A combination of specific neurologic, cardiovascular, musculoskeletal and
endocrine findings points towards a FA diagnosis.61 Age of onset is typically before
puberty, although it can sometimes present in early infancy to late adulthood.62 However,
late onset after 25 years of age of the disease does occur in approximately 15% of the
FA cases.61

Neurologic symptoms often present first in the form of ataxia, loss of

sensation or weakness in limbs and impaired speech.

Similarly, musculoskeletal

weakness and scoliosis are trademarks for FA. Most of disease treatment focuses on
managing cardiovascular health since cardiomyopathy is the primary cause of death for
60% of FA patients.62 Other compounding phenotypes are the development of diabetes,
glucose intolerance and auditory impairment.61
Presentation of these phenotypes becomes apparent based on the mechanism of
cellular death. Based on the ubiquitous roles of Fe-S clusters for function it is not
surprising to see widespread effects. In certain tissues, frataxin is poorly expressed
leading to mis regulation of cluster assembly, mitochondrial iron, mitochondrial ferritin
stores and hemoglobin synthesis.63 The most problematic cellular consequence is the
generation of reactive oxygen species (ROS) in the mitochondria. ROS production rapidly
damages cells by Fenton reaction. Byproducts of the fenton reaction can attack proteins,
fatty acids and DNA. In the case of FA, these reactions occur more heavily in specific
tissue sites leading to cardiovascular and neurodegeneration.61
1.4.1 Molecular basis of FA
The cause of FRDA was identified as a mutation in the frataxin gene (FXN) on
chromosome 9q13.64, 65 A GAA triplet expansion on the gene causes poor expression of
the protein frataxin. Normal alleles have 5-33 repeats but in FA the expansion is much
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larger.66 The size of the expansion, which can be from 100 to 1700 repeats or more, can
correlate to severity of the disease.62 Although a majority of FRDA cases are the result
of the triplet expansion, a few percent (4) of cases are the result of point mutations in FXN
protein.66
1.4.2 Summary of past and emerging treatment options for FA
There are no curative agents for FA and consequently, clinical strategies are often
focused on symptom management. For example, antipsychotics, steroids and statins
have been tested to improve neurological or cardiac function to extend lifespan.62 Earlier
strategies targeted generation of ROS and iron accumulation through antioxidant and
chelation therapy. Clinical improvement after treatment with these agents remains
controversial and they are unable to restore Fe-S cluster production and mitochondrial
iron trafficking.62 As a consequence, newer strategies aim to increase frataxin expression
or stability. Of the 56 clinical trials that are current or have been completed, 42 are focused
on drug testing (clinicaltrials.gov).

Most of these studies have been completed or

terminated and only 4 trials are active or currently recruiting. A summary of current and
past clinical trial candidates is shown in Figure 1.4. Despite the number of completed
studies, there is still no effective therapeutic for FA therefore, development of further
treatment options is critical.
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Chelation
Therapy

Antioxidant/
Mitochondrial
function

Increase FXN

Other

Deferiprone
Epicatechin

EPI-734*
RTA408*
Idebenone
Epicatechin
RT001
VP20629
EGb761
A001

nicotinamide*
resveratrol*
MIN-102*
interferon
gamma
pioglitazone
erythropoeitin

Rosuvastatin
methylprednisolone
TAK-831
buproprion/
citalopram

Figure 1.4 . Summary of clinical trials for Friedreich’s Ataxia. Clinical trials are listed
based on therapeutic strategy and are either in progress*(not yet recruiting, recruiting
enrolling by invite, active) or finished (suspended, terminated, completed).

20
Antioxidants are found in biology and synthesized for their ability to mitigate
damage by ROS. Production of ROS is high for patients with FA.67 Dietary antioxidants
alone are not enough for therapeutic level.62 While antioxidants can reduce damage from
ROS, they often lack specificity and are unable to improve cluster formation or increase
frataxin expression. Highlighted here are a few of many antioxidant therapies available
for FA. Coenzyme Q10 is found naturally in the electron transport chain in the
mitochondria and provides an electron shuttling function.62 Idebenone is a synthetic
analogue of CoQ10. Some studies have shown idebenone to improve cardiac function
but not neurological function.68,69 However, other reports dispute these findings and
criticize a small sample size for the study.70 There are multiple trials underway
investigating the use of Idebenone for FA. EPI-743 is a synthetic drug based off of the
antioxidant function of vitamin E. An active phase 2 trial has completed in December
currently under phase I clinical trial for its use in disorders of energy utilization and
oxidation-reduction (clinicaltrials.gov) and also phase 2 trial for improvement in visual
function for FA patients. While antioxidants can relieve oxidative stress, they are not able
to target deficiencies in cluster production.
Chelation therapies are aimed at lowering excess mitochondrial iron, a key cellular
phenotype of FA. Deferiprone, for instance, is an iron binding chelator which can cross
the blood brain barrier

62

has shown the possibility to reduce disease progression with

low dose treatment.71 However, further studies related to FA have stalled. Desferoxamine
is widely used for its iron chelation abilities in diseases of iron overload. It does not have
the ability to cross the blood brain barrier. However, desferoxamine has a high affinity for
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iron and can deplete off target iron.72 No active clinical trials are in process for chelation
therapy for FA.
Antioxidants and chelation therapies have been long investigated with mixed
results. Therefore, new therapeutic options are critical to patient outcome. Increasing
frataxin expression has been shown for drugs such as erythropoietin, interferon and
HDAC inhibitors.62, 72 Erythropoietin, however, was unable to have significant effects on
frataxin expression in human trials.72,73 Interferon gamma modulates frataxin mRNA and
clinical trials are currently underway. HDAC inhibitors such as nicotinamide aim to
improve protein expression by inhibiting chromatin silencing. While nicotinamide was
effective early on and showed an increase in frataxin levels, there was no clinical
benefit.72,74 Efforts to increase frataxin expression often fall short in human trials
compared after promising results in cell lines or animal models. An emerging strategy to
increase frataxin expression is through adeno-associated virus (AAV) delivery.75 This
has shown to be effective in animal models however, movement to human trials face
challenges such as genotoxicity.76

1.5 Summary
Fe-S clusters are diverse cofactors with an ancient past and ever-expanding
future. Since the initial discovery of Fe-S clusters as electron shuttling cofactors, new
roles for clusters have been discovered. The electron shuttling function is demonstrated
by electron transport chain complexes containing multiple Fe-S clusters of different size.
New roles for Fe-S clusters have been discovered ranging from metabolic catalysis,
oxygen sensing, iron homeostasis, DNA regulation, protein stabilization. Fe-S cluster
assembly is achieved in the mitochondria and cytosol however mitochondrial Fe-S cluster
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biosynthesis is critical for understanding Friedreich’s Ataxia. FA is hallmarked by its
cardiovascular and neurodegenerative phenotypes as a result of mitochondrial iron
overload. Treatment strategies, therefore, have focused on antioxidant and chelation
therapy but have yielded limited and controversial success. Newer candidates have
emerged aimed at increasing frataxin expression by stabilizing mRNA, modifying
chromatin structure or through delivery by adenovirus therapy. Unfortunately, there are
only a few clinical trials currently underway investigating these new therapies leaving a
demand for the development of new targets. Our work is significant in that we aim to
develop a more accurate mechanism for mitochondrial Fe-S cluster biosynthesis which
potentially could identify a new target site.

For instance, use of a frataxin peptide

designed to mimic iron delivery and interface with Isu1 is one possible direction.
However, designing a functional peptide requires a thorough and accurate mechanism of
Fe-S cluster synthesis especially the roles of Isu1 and frataxin. The goal of this work is
to identify the dynamic nature of Isu1 in cluster assembly related to metal binding events
and structure-function activity.
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CHAPTER 2: UNIQUE ROLES OF IRON AND ZINC BINDING TO THE
YEAST FE-S CLUSTER SCAFFOLD ASSEMBLY PROTEIN “ISU1”
2.0 Prelude
This work began as a curiosity why Isu1, and iron sulfur protein, was also shown
to bind zinc. The purpose of this chapter is to describe the nature of Zn and Fe binding
to Isu1 and how Zn affects cluster assembly activity. Another goal was to compare iron
binding across orthologs to determine if iron binding is conserved. Overall, this work
provided critical data to show the complex nature of Isu1 with respect to metal loading
events. This chapter is adapted from a recently submitted manuscript to Metallomics
sharing the title of this chapter. I contributed most of the data for this manuscript with
assistance from Dr. Paul Lindahl’s group for Mossbauer, former graduate student Dr.
Andria Rodrigues who completed ortholog XAS studies and Dr. James Cowan for human
ISCU constructs. Additionally, Zachary Mason, an undergraduate student who I have
mentored over the last few years, contributed some of the CD spectra and assisted with
protein purification. All contributing authors and institutions for the manuscript are listed
below:
Brianne E. Lewis‡, Zachary Mason‡, Andria V. Rodrigues‡, Gregory P. Holmes-Hampton€,
Shaik Waseem Vali#, Manunya Nuth°, Eric Dizin°, J. A. Cowan°, Paul A. Lindahl€,# and
Timothy L. Stemmler ‡,*
‡

Department of Pharmaceutical Science, Wayne State University, Detroit, MI 48201;

°Department of Chemistry, The Ohio State University, Columbus, OH 43210;
€

Department of Chemistry, Texas A&M University, College Station, TX 77843.
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Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX

77843.

2.1 Introduction
Metal homeostasis is central for the viability of nearly every cell.77

Iron

homeostasis in particular is critical for biology; iron’s varied redox capabilities and high
prevalence within nature make it often the metal of choice to assist metalloproteins in
performing complex chemistry that cells cannot perform using only an organic toolkit.78, 79
Iron, often incorporated into Fe-S clusters, plays a pivotal role in several essential
biochemical pathways, including: sensing oxidative stress in the cytosol, directing DNA
repair within the nucleus and driving cellular respiration inside the mitochondria.80-82 FeS cluster biogenesis in eukaryotes occurs predominately within the mitochondria.41, 83 In
yeast, Fe-S cluster assembly is accomplished directly on the scaffold protein (Isu1), using
sulfur in the form of a persulfide provided by the cysteine desulfurase (Nfs1) enzyme.84,
85

Nfs1 works in complex with the yeast accessory protein (Isd11) and the acetyl carrier

protein (Acp1) to accomplish its enzymatic activity.49, 86-88 Electrons, essential for forming
and stabilizing Fe-S clusters produced on the Isu1 template, are provided by the yeast
ferredoxin (Fdx1).89 Yeast frataxin (Yfh1), an iron binding protein that regulates cysteine
desulfurase activity, also plays a pivotal but unconfirmed role in Fe delivery to Isu1.45, 9098

During Fe-S cluster assembly, several scaffold orthologs have been shown to

interconvert between disordered and structured states, indicating a dynamic interplay
within the protein itself and/or between scaffold and protein partners essential for
assembly to occur; this dynamic mobility on Isu1 may help drive substrate delivery to,
[2Fe-2S] assembly of, and delivery by the scaffold.45, 51, 53, 99
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Several studies have probed the biophysical aspects of iron binding to different
scaffold orthologs.42, 53-55 The yeast and fly scaffolds (Isu1 and fIscU, respectively), which
have high sequence homology, bind two Fe(II) atoms with affinities in the µM to sub-µM
range;

55

similar Fe(II) binding affinities have been reported for the human and bacterial

scaffold orthologs.100 In the yeast and fly orthologs, iron coordinates to the scaffold in an
environment dominated by oxygen and nitrogen based ligands, suggesting ferrous ions
are coordinating at a site on the protein distinct from its Cys rich active site.55, 54 While the
protein partner(s) used to accomplish Fe(II) delivery to the scaffold during in vivo Fe-S
cluster assembly remains elusive, a recent report indicates that human frataxin promotes
delivery of Fe(II) to the human scaffold (ISCU) in order to activate Fe-S cluster
assembly.101 In this system, frataxin-mediated Fe delivery occurred only when both Lcysteine and reductant (human ferrodoxin “FDX2” or DTT) were provided, and these data
would be consistent with Fe(II)-loaded frataxin being a source for iron delivered to scaffold
during mitochondrial Fe-S cluster assembly.101 The mechanisms for delivery of Fe(II) to
the frataxin ortholog remains unknown, however a low-molecular mass iron complex
found within mitochondria could be the candidate for the iron that is utilized for Fe-S
assembly.102,

103

Given the ca. 10 µM affinity of Fe(II) to Yfh1 and an estimated

concentration of ~ 150 µM for the nonheme high-spin Fe(II) pool in mitochondria104, it
seems reasonable that frataxin is predominately iron loaded within the organelle and
therefore positioned to direct the transfer of Fe(II) to the scaffold as a central event driving
Fe-S cluster assembly, when all the proteins are part of the Fe-S cluster assembly protein
complex.90 Finally, in yeast, Yfh1 binds directly to Isu1 in an iron dependent manner at a
1:1 stoichiometry with micromolar binding affinity, however human frataxin has been
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reported to only bind to the human scaffold (ISCU) when associated as part of a multiprotein assembly complex, so additional clarification of metal loading and protein
complexation formation events in the pathway need to be explored.45, 101
Zinc stabilizes the scaffold within its structured conformation and the metal also
inhibits scaffold activity during Fe-S cluster assembly. Structural data from the bacterial
and human orthologs structures confirm zinc coordinates directly to cysteine residues at
the scaffold’s active site.42,

56, 105, 106

Furthermore, zinc was used to stabilize human

ISCU’s structure when the protein was part of the Fe-S cluster assembly complex that
included

the

bacterial

acetyl

carrier

protein,

within

the

assembly

of

the

[NFS1]2[ISD11]2[Acp]2[ISCU]2 protein complex stoichiometry (referred from here on as
“NIAU”).42 Biochemically, zinc coordination was suggested to be an artifact of bacterial
IscU overexpression, and the extent of zinc loading was shown to be variable in relation
to changes in the cell growth conditions.57 Zinc coordination to ISCU negatively inhibits
the cysteine desulfurase activity within the human NIAU complex, as a result of zinc
ligating to ISCU active site residues (Asp 71, Cys95 and His137) and the NFS1 active
site persulfide forming/transfer residue (Cys381); Zn coordination likely inhibited
persulfide production by reducing the availability of essential active-site residues from
both proteins.57 Interestingly, in this study it was also shown that human frataxin restores
cysteine desulfurase activity by the NIAU complex once frataxin was coordinated.107
Here we perform a biophysical characterization of both Fe(II) and Zn(II) binding to
the yeast scaffold Isu1. Iron and zinc binding affinities to Isu1 were determined using an
in vitro metal binding competition assay developed to measure Fe(II) binding for proteins
under conditions that better resemble in vivo binding environments experienced by apo-
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proteins in cells.54 The impact of Fe and/or Zn binding relative to coordination by the
alternate metal, the influence of metal binding on the scaffold structure, and the control
of metals on scaffold’s cluster assembly activity have been characterized in this report.
Furthermore, we performed a structural and electronic characterization comparison of
Fe(II) bound to the yeast, fly, human and bacterial scaffold orthologs. Our overall objective
was to provide the molecular details needed to better understand scaffold iron-loading
events that drive Fe-S cluster assembly. In addition, we wanted to explore if zinc plays a
role in Fe-S cluster assembly, to investigate if zinc can serve as a tool to help us evaluate
not just the structure but the function of the scaffold, and to characterize details related to
Zn’s ability to alter the activity of the yeast cluster assembly complex.

2.2 METHODS
2.2.1 Sc Isu1 Expression and Purification
The wild type Isu1 (S. cerevisiae) gene was transformed into C41(DE3) cells and
incorporated into a pET21b-mIsu1 plasmid for protein expression (Lucigen), as outlined
previously.54 Cells were grown with Ampicillin (0.1µg/µL) in Luria-Bertani broth at 37°C
and shaken at 250 rpm. Cells were induced with a final concentration of 0.8 mM IPTG at
an OD600 of 0.6.

Following induction, cells were grown for an additional 3 hr and

harvested by centrifugation at 8000 rpm for 20 min at 4˚C. Cells were stored as a pellet
at -80˚C until lysing. All isolation steps were performed at 4˚C following our published
protocol outlined below.54, 55 Frozen cells were resuspended in 50 mM NaPO4, 300 mM
NaCl, 20 mM Imidazole and 5 mM b-Me binding buffer, pH 7.5, in the presence of
Complete EDTA free Protease inhibitor cocktail tablets (Roche). Cells were lysed by
three passes through an Emulsaflex (ATA Scientific), followed by centrifugation at 21,000
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rpm for 60 min.55 Crude fractions were filtered first through a 0.4 µm then 0.2 µm sterile
filter. Soluble fractions were loaded onto a 5 mL His-Trap purification column (GE
Healthcare) pre-equilibrated with binding buffer. Protein was eluted using an imidazole
gradient between 20 - 500 mM imidazole concentrations. Isu1 fractions were pooled,
concentrated and dialyzed (2 buffer exchanges for 3 hr each in 2L volume) against 20
mM HEPES, 300 mM NaCl, 10 mM EDTA and 5 mM b-Me (pH 7.5) buffer. Dialyzed
samples were passed through a Sephadex 75 (GE Healthcare) size exclusion column
equilibrated with 20 mM HEPES, 300 mM NaCl, 10 mM EDTA and 5 mM b-Me (pH 7.5)
buffer. Isu1 eluted from the column as a single species at an estimated 95% purity, as
judged by the presence of only a single A280 peak in the chromatograph, and from SDSpage gel analysis from a 4-20% polyacrylamide gel.45

Protein samples were dialyzed

into storage buffer (20 mM HEPES, 300 mM NaCl and 5 mM TCEP (pH 7.5)),
concentrated to 600 µM and stored at 4°C within an anaerobic chamber. Isolation
protocols for the fly, bacterial and human scaffold orthologs have been published
previously.55, 99, 108, 109 ICP-MS analysis for all apo-Isu1 samples were performed at the
University of Utah Health Sciences Protein Core Facility (http://cores.utah.edu/massspectrometry-proteomics/) to determine the average metal contaminations (Fe or Zn) for
the protein following our isolation protocol. Average metal concentrations for as isolated
“apo”-Isu1 at 1 mM protein concentrations were 2.1 ± 1.0 µM Fe and 3.5 ± 2.6 µM Zn,
representing a ca. 0.2% metal contaminant for Fe and Zn bound to isolated apo-protein.
2.2.2 Fe or Zn Protein-Binding Competition Assays
Individual iron or zinc metal binding affinities to Isu1 were determined according to
our recently reported competition assay that uses mag-fura-2 (Molecular Probes) as a
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metal chelator that works in competition with the protein during affinity characterization.54,
55

As previously outlined, mag-fura-2 forms a 1:1 complex with the divalent cations (Fe

and Zn) displaying a maximum absorbance at 325 nm when either metal is bound or a
feature at 366 nm when in its apo state.54 The progressive reduction of absorbance at
366 nm indicative of metal loading was measured using a Shimadzu UV-1800
spectrophotometer housed within a wet anaerobic chamber (Coy Lab Products). Titration
data, obtained by adding divalent metal ion in sub-stoichiometric equivalents into an
Isu1/mag-fura-2 mixture, were collected anaerobically at room temperature using a 1 cm
quartz cuvette. Due to overlap between the Fe- and Zn-loaded mag-fura-2 signals, we
could not distinguish specific changes in metal binding activity when both metals were
added, so we were limited to measuring metal binding affinities only for individual metals
binding to protein. All samples were prepared anaerobically in 20 mM HEPES and 300
mM NaCl (pH 7.5) running buffer for use during binding analysis.
Specific details for the experiments and protocols for anaerobic preparation of the
samples are outlined below.

All septa capped reagents/buffers were bubbled with

hydrated Ar(g) while stirring for 30 minutes, and then were then stored capped within the
Coy anaerobic wet chamber overnight prior to experimentation. Several independent apoprotein samples, incubated with 5 mM TCEP in running buffer prior to titrations, were
dialyzed within the anaerobic chamber along with running buffer to remove the TCEP
prior to metal loading. Metal and chelator samples were prepared and data collected
using only running buffer within the oxygen free environment. During the titration, magfura-2 concentrations were varied between 0 and 8 µM, while the protein concentration
was held constant at 4 µM, under multiple independent data set collections. An anaerobic
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solution of 2.0 mM ammonium ferrous sulfate hexahydrate (Sigma), prepared in running
buffer was added in progressive sub-stoichiometric increments to the protein/mag-fura-2
mixture until signal saturation was reached. After each addition, an absorption spectrum
was collected between the wavelength range of 200 - 800 nm.

Zn titrations were

performed in the identical manner but using a 2.0 mM zinc sulfate (Sigma) solution to
substitute the iron. Initial apo mag-fura-2 concentrations were determined using the molar
absorptivity (e) value of 29,900 M-1cm-1 for the compound, and values were measured at
the wavelength of 366 nm.54 The absorbance at 366 nm, corrected for dilution, was then
used to calculate binding parameters for the protein relative to the amount of metal added.
Binding data were simulated with the program DYNAFIT110 using a non-linear least
squares analysis script to identify the binding capacity and metal stoichiometry for the
protein distinct from mag-fura-2, in a manner previously outlined.54,

55

Each titration

experiment was simulated using both one and two-site metal binding models for
comparison.
2.2.3 Circular Dichroism of Fe and/or Zn Bound Isu1
The impact of metal binding on Isu1’s secondary structure was measured in the
presence of bound Fe and/or Zn by circular dichroism (CD) spectroscopy. Samples of
apo- and holo-Isu1 were prepared within a Coy wet anaerobic chamber from the identical
anaerobic protein stock solution. CD spectra of apo- and metal loaded Isu1 samples were
collected using a 0.1 cm anaerobic quartz cuvette on a benchtop Jasco 1500
spectrophotometer, equipped with a Peltier VT unit set at 27 °C. Apo- and Fe-loaded
Isu1 samples were prepared in 1 mM NaPO4 buffer (pH 7.5), whereas Zn-loaded Iscu1
samples were prepared in 5mM NaPO4 buffer (pH 7.5); the buffer change was to improve
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the stability of Isu1 since lower salt caused the protein to ppt when loading Zn. For holoIsu1 samples, 1 equivalent of Zn(II)(aq) or 2 equivalents of Fe(II)(aq) were added to the
anaerobic protein solution. Each sample had a final protein concentration of 10 µM; this
protein concentration was chosen, given the Kd’s measured for metal binding, to ensure
that the majority of the protein in our CD samples were metal loaded. Twenty scans total
were collected and averaged for each final spectrum, and spectra on independent
duplicate samples were collected to ensure data reproducibility. Before protein spectral
collection, a baseline at all wavelengths was collected and used for subtraction for protein
data to eliminate buffer signals. Spectra were analyzed using the Jasco CD Pro analysis
software and simulated using the CONTIN method using the SP29, SP37, SP43, SMP50
and SMP56 spectral reference sets.111 Values obtained from simulations from each
database were averaged to obtain final CD simulation analysis parameters.
2.2.4 X-ray Absorption Spectroscopy
X-ray absorption spectroscopy (XAS) was used to characterize the structure of
metal bound to the scaffold in solution. Metal loaded protein XAS samples were prepared
anaerobically within a Coy chamber using solution samples dialyzed in hydrated Ar buffer
(protein) or by dissolving metal salt samples in buffer prepared with Ar bubbling. Yeast
Isu1 XAS samples were prepared at a 1.0 mM final protein concentration in 20 mM
HEPES (pH 7.0), 300 mM NaCl and 5 mM β-Me buffer. Isu1 XAS spectra were collected
at the Stanford Synchrotron Radiation Lightsource (SSRL) on beamline 9-3. Duplicate
independent samples were loaded with 1.9 equivalents of Fe(II) per 1 equivalent of
protein using an ammonium ferrous sulfate hexahydrate solution and/or with 0.9
equivalents of Zn per 1 equivalent of protein using a zinc sulfate solution; protein was in
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slight excess to ensure all metal was bound to the protein. XAS data for scaffold orthologs
from H. sapien, D. melanogaster, and T. maritima, as well as an additional verification of
the S. cerevisiae Isu1 control sample, were collected on duplicate independent samples
at SSRL on beamline 7-3 and at the National Synchrotron Radiation Laboratory on
beamline X3b. Ortholog comparison samples were loaded with only 0.95 equivalents of
ferrous salt per 1 equivalent protein for consistency. All XAS samples were diluted to 0.7
mM final protein concentrations by addition to 30% glycerol as a glassing agent. Samples
were then loaded into XAS Lucite sample cells wrapped with Kapton tape, flash frozen in
liquid nitrogen, removed from the glove box and finally stored in liquid nitrogen until data
collection. SSRL beamlines 7-3 and 9-3 were equipped with a Si[220] double-crystal
monochromator, while NSLS beamline X3b was equipped with a Si[111] single-crystal
monochromator. All beamlines are equipped with focusing mirrors for harmonic rejection.
Fluorescence spectra were collected using a Canberra 100-element on beamline 9-3 or
30-element Ge solid state detectors at beamlines 7-3 and X3b. During data collection,
samples were maintained at 10 K using an Oxford Instruments continuous flow liquid
helium cryostat at both SSRL beamlines or at ca. 24 K using a helium Displex Cryostat
at NSLS. Beamline 9-3 XAS data were collected with a 6 µm Mn or a 6 µm Cu filter placed
between the cryostat and the detector to reduce unassociated scattering for the Fe and
the Zn XAS, respectively. During data collection, a Fe or Zn foil spectrum were collected
simultaneously with the protein data for spectral energy calibration. XAS spectra were
recorded using 5 eV steps within the pre-edge region, 0.25 eV steps within the edge
region and 0.05 Å-1 increments within the extended X-ray absorption fine structure
(EXAFS) region. Data were collected out to k = 13 Å-1 for both elements, integrating from
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1 to 25 s in a k3-weighted manner. An average of 6 (beamline 9-3) to 10 (beamlines 7-3
and X3b) individual scans were collected for each sample and these were averaged for
analysis. Each scan lasted approximately 40 minutes. Each spectrum was closely
monitored for X-ray induced radiation damage of the sample.
XAS spectra were processed and analyzed using the EXAFSPAK program suite
written for Macintosh OS X.112 Fluorescence scans corresponding to each channel were
examined for anomalies. A Gaussian function was fit to the pre-edge region and a cubic
spline was fit to the EXAFS region of the data for baseline subtraction. Spectra were
simulated using single and multiple scattering amplitude and phase functions generated
by the Feff v7.2 (7-3 and X3b data) and v8.0 (for 9-3 data) software packages; Feff was
integrated directly within the EXAFSPAK software.113 Calibrations of the theoretical scale
factors (Sc) and energy shift (E0) values were obtained by fitting crystallographically
characterized compounds to provide the Sc and E0 values utilized during our protein data
simulations.44

Calibrated Sc and E0 values were held static during empirical data

simulations, using the dimensionless Sc value of 0.95 for both Zn and Fe samples. E0
values for protein Fe-O/N/C simulations were set at -11.5 eV44. E0 values used to fit
protein Zn-O/N/C/S interactions were set at -15.25 eV114. All Fe and Zn EXAFS data were
fit over a k range of 1 to 13.0 and to 1 to 12.5 Å-1, respectively. EXAFS spectra were
simulated using both filtered and unfiltered data, however only simulations of unfiltered
data are presented in this report. Simulation protocols and criteria for determining the best
fit to the empirical data have been described previously.44
2.2.5. Mössbauer Spectroscopy and LC-ICP-MS
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An 57Fe stock solution was prepared by mixing 57Fe metal powder in concentrated
aqua regia to a final concentration of 80 mM FeCl3. This solution was transferred into a
glove box, a 10-fold molar excess of ascorbic acid was added and the resulting solution
was diluted to 40 mM 57Fe concentration. The first Mössbauer (MB) sample was prepared
by mixing 3 mL of ca. 100 µM recombinant Isu1 with 7.2 µL of 57Fe(II) ascorbate (ca. 95
µM final concentration, from stock) within an anaerobic refrigerated glove box and sample
was incubated for 1 hr. The protein was concentrated to ca. 400 µM using an Ultracel
10 kDa ultracentrifugation regenerated cellulose disk (EMD Millipore) in a Model 3 Amicon
Filtration system. About 700 µL of retentate was transferred to a MB cup and frozen in
liquid N2. MB data was collected at 5 K on a MS4 WRC spectrometer (SEE Co., Edina,
MN) and simulated using WMOSS software (http://www.wmoss.org/). The instrument was
calibrated at room temperature with an α-iron foil. After data collection, the sample was
thawed within the glovebox and 300 µL was injected onto Superdex 200 - 10/300 GL (GE
Healthcare) column equilibrated in 20 mM Tris, 10 mM NaCl (pH 7.4) buffer. This system
was coupled online to an LC-ICP-MS, as described previously, for metal detection
following Mössbauer/LC-ICP-MS combined analysis;115 original isolated apo-protein was
determined to have 0.2% and 0.1% Fe and Zn contamination, respectively (see above).
Since metal contaminates again were observed in the LC-ICP-MS analysis of the first
Mössbauer, a second apo-protein sample was prepared for Mössbauer from as-isolated
protein that was dialyzed in high EDTA (100 mM) to remove all metal contaminates. Prior
to
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Fe metal loading, protein was dialyzed with EDTA free collection buffer, however

sample showed turbidity even upon filtration.

The second MB sample was metal

loaded and analyzed by MB and LC-ICP-MS as described above. The second MB sample
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utilized for inline Mössbauer and LC-ICP-MS analysis was prepared by mixing 2.6 mL of
a ca. 120 µM protein solution with 7.2 µL of the stock 57Fe(II) ascorbate solution (ca. 110
µM final concentration).
2.2.6 Fe-S Cluster Formation Assay
Fe-S cluster assembly was measured for the yeast NIaUF protein complex (all
yeast proteins except bacterial Acp) following our previously published protocol.55 All
solutions and reagents were made anaerobic by bubbling with hydrated Ar(g), while
protein was prepared anaerobic by extensive dialysis within hydrated Ar(g) bubbled
buffer. Protein was stored on ice within our Coy anaerobic chamber until used in the
assembly assay. The reaction buffer used during cluster assembly contained 20 mM
HEPES and 300 mM NaCl (pH 7.5). Reagents and apo-Isu1 samples were mixed within
the Coy chamber in the following amounts: 10 µM Nfs1-Isd11 complex, 50 µM Isu1, 10
µM Yfh1, 500 µM L-Cys, 5 mM DTT and 75 µM Fe(II)(aq). Fe-S cluster assembly was
measured in the presence and absence of 1 equivalent of buffered Zn(II)(aq); Zn was
preloaded onto Isu1 before combining the reaction mixture. Following addition of Fe(II),
samples were placed in a 1 cm pathlength anaerobic CD cuvette and quickly transferred
to the Jasco-1500 Spectrophotometer for data collection (with an average of a 30 second
dead time during transfer). CD spectra were measured at 430 nm for 60 minutes to
monitor cluster formation activity, as previously reported.55 Data were signal averaged
from 3 independent measurements and the experiment was performed in duplicate on
proteins isolated from independent preparations.
2.2.7 Sequence Alignment of Orthologs and the Modeled Structure of Zn-Isu1
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Amino acid sequences of the scaffold orthologs were obtained from the GeneBank
depository (yeast #KZV07380.1, Fly #NP_649840, Human #ACA52543 and Thermatoga
#Q9X192, respectively) and all sequences were aligned using the Clustal Omega
software package.116 A modeled Zn-Isu1 structure, constructed using the program ITasser, was based on the human ISCU crystal structure (PDB #5WLW) as the reference
template for the initial molecular architecture.42, 117, 118 The NCBI-yeast Isu1 sequence
was used as the query protein. Zinc placement within the structure was modelled using
the Zn XAS metrical parameters obtained from Zn bond lengths and coordination
characterization information outlined within this report.

The modeled structure was

colored using PyMOL software.119

2.3 RESULTS
2.3.1 Iron and Zinc-Binding Characteristics of Isu1
To better understand Isu1’s iron and zinc binding characteristics, we determined
metal binding affinities and the metal:protein stoichiometries for the yeast scaffold using
our competition metal binding assay; this competition assay better reflects the
heterogeneous binding environment experienced by proteins in vivo.120 Mag-fura-2 is a
useful chelator for measuring binding events under competition conditions for both Fe(II)
and Zn(II) metals since it’s affinity is tuned closely to that seen for these proteins.54, 121
Apo-mag-fura-2 has a well-established spectroscopic signal at 366 nm (peak maximum)
that shifts to 325 nm upon Fe(II) or Zn(II) binding (Figure 2.1A & B, respectively).
Progressive iron or zinc binding causes a decay in the 366 nm absorbance maximum
(Figure 2.1 C & D, respectively); this decay profile can be simulated to obtain protein
metal-binding characteristics (Table 2.1).54 Simulations of Fe(II) titrations into the mag-
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fura-2/Isu1 competitive mixture indicated an optimal binding stoichiometry of ca. 2 iron
ions to 1 Isu1, with relative dissociation constants of Kd1 = 3.5 ± 1.8 and Kd2 = 10 ± 8.6
µM. Simulations of Zn titrations into the mag-fura-2/Isu1 mixture indicated an optimal
binding stoichiometry of 1 zinc ion to 1 Isu1 molecule, with a single dissociation constant
of Kd = 0.44 ± 0.19 µM. The Zn binding value for Isu1 is tighter than that reported for
bacterial IscU (5.8 µM) but slightly weaker than that measured for the human ortholog
(0.16 µM).57, 122 We were unable to measure binding in the presence of both Fe and Zn
since spectroscopic signals from both Fe and Zn-loaded mag-fura-2 significantly overlap,
hence preventing deconvolution of each binding interaction within a mixed metal
environment. All binding data were collected under anaerobic conditions to avoid protein
oxidation and to stabilize the redox state of the aqueous Fe(II).
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Figure 2.1 Fe and Zn Binding Affinity to Isu1 Measured using Mag-Fura-2 within a
Competition Based Assay. (A) Representative titration spectra of iron into Isu1 and (B)
zinc into Isu1. Mag-fura-2 to protein ratio was varied from 1:2 (red), 1:1 (black), 2:1 (blue)
for Fe (C) and Zn titrations (D), respectively. Spectra were collected in duplicate using
independent samples to ensure spectral reproducibility.
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Sample

Kd1

Kd2

Fe:Mag-Fura-2

3.5 µM ± 1.8 µM

10 µM ± 8.6 µM

Zn: Mag-Fura-2

0.44 µM ± 0.19 µM

----

Table 2.1 Summary of Binding Affinity Measured in Mag-Fura-2 Competition Assay.
Assay was performed at 25.0 °C under anaerobic conditions, with binding parameters
determined by simulating the signal values at 366 nm using DynaFit.110 Metal to protein
stoichiometry was best fit using a 2:1 binding model for Fe-Isu1 and a 1:1 binding model
for Zn-Isu1.
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In a previous report, we characterized the iron binding affinity for D37A- and wtIsu1 using Isothermal Titration Calorimetry (ITC).45,

54

These metal binding values,

obtained by ITC, are compared to values obtained from the competition assay for wt-Isu1
from this report. All measurements were performed at the same pH and buffering
capacity, however the salt concentration in the previous reports were with lower (150 mM
NaCl). The higher salt concentration in this report was used to better stabilize both the
Fe and Zn-loaded protein. Using ITC, we determined D37A-Isu1 binds 2 Fe(II) atoms
with Kd values of 2.0 and 0.006 µM, while for wt-Isu1 measurements, affinities were 1.0
and 0.02 µM; the 2 Fe binding affinities in this report using our competition assay were
3.5 and 10 µM. The primary binding affinity in all Isu1 measurements were similar
(between 3.5 and 1.0) and these values were close to the Kd’s measured for the human
and bacterial orthologs at 2.0 ± 0.2 µM and 2.7 µM, respectively.108 The second affinity
measured by ITC was consistently much lower than the second value measured using
the competition assay, possibly indicating real differences in the second metal binding
under homogeneous vs. heterogeneous binding environments. Alternatively, the second
affinity measured by ITC may represent a thermodynamic event unrelated to metal
binding.
2.3.2 Structural Changes on Isu1 Concurrent with Fe and Zn Binding
Circular dichroism (CD) spectroscopy was used to determine if the secondary
structure of Isu1 is altered due to iron or zinc binding. Previous Fe(II) and Zn(II) titrations
into bacterial IscU showed that while Fe(II) binding caused only a minimal impact on the
IscU fold, Zn(II) binding dramatically increased the helical fold of the metal-loaded
protein.122 In our study, all CD spectra were collected under anaerobic conditions to avoid
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metal/protein oxidation. Averaged CD spectra comparing apo-Isu1 with Isu1 loaded with
either Fe or Zn, are shown in Figure 2.2A and B, respectively. Average secondary
structural fold parameters obtained from simulations of these data in the far UV-region
are listed in Table 2.2. Comparison of spectra for apo- vs. Fe(II) loaded Isu1 show a high
similarity in overall spectral signature. In contrast, addition of a single equivalent of Zn(II)
into Isu1 induces a noticeable change in the overall spectrum, with a relative increase in
the 223 nm signal and a shift in the apo-protein’s 203 nm signal towards 208 nm,
consistent with an increase in a-helix content for the Zn loaded sample. Simulation
parameters for the apo- and Fe(II)-loaded sample are nearly identical, however
parameters from the Zn-Isu1 CD data confirm an overall enhancement (ca. 12% in overall
fold) in the helical content relative to the apo- and Fe(II)-Isu1 samples and a relative
decrease (ca. 11% in overall fold) in b-sheet content for the Zn sample. These structural
parameters are consistent with measured values obtained from Zn(II) bound human
ISCU.57 A high helical content in Zn-Isu1 is also consistent with the high helicity observed
in the human Zn-ISCU crystal structure.42, 43 Overall, these data confirm Zn drives Isu1
into an enhanced structured state while Fe alone does not.
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Figure 2.2 Circular Dichroism of Apo, Fe- and Zn-Loaded Isu1. Representative
spectra of apo- (solid line) and 2Fe-loaded (dashed line) Isu1 in panel (A). Representative
spectra of apo- (solid) and Zn-loaded (dashed) Isu1 in panel (B). An average of 30 scans
were collected for each representative spectrum displayed; trials were performed in
duplicate with independent samples to ensure spectral reproducibility.
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Sample
apo-Isu1

a
16.5 ± 8.4

b
26.7 ± 10.5

O
23.8 ± 2.3

D
33.0 ± 0.7

Fit a
0.04

2Fe-Isu1

16.0 ± 3.1

26.7 ± 3.3

23.5 ± 0.9

34.0 ± 2.8

0.05

1Zn-Isu1

27.9 ± 0.5

15.0 ± 0.7

24.6 ± 0.1

32.5 ± 0.1

0.05

1Zn-ISCU b

44

20

35

21

NA

Table 2.2 Circular Dichroism Fitting Percent Parameters of Apo, Fe and Zn-Loaded
Isu1. Secondary structural abbreviations include a (alpha-helix), b (beta-sheet), O
(structured other) and D (disordered).
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2.3.3 XAS Analysis for Fe and Zn Sites Coordinated to Isu1
X-ray absorption spectroscopy (XAS) was used to characterize metal electronic
and structural parameters for iron and zinc loaded individually and in combination to Isu1.
X-ray absorption near edge spectroscopy (XANES) provides insight into the metal
oxidation state and metal-ligand structural symmetry. Iron XANES for Fe(II)-Isu1 are
consistent with ferrous metal bound to the protein in a pseudosymmetric 6-coordinatel
ligand environment constructed by oxygen and nitrogen ligands (Figure 2.3A).45, 54, 123
Iron XANES for both the Fe- and Zn/Fe- loaded Isu1 samples are similar in overall
spectral nature, suggesting the Fe coordination environment does not change
significantly when zinc is also added to the protein sample. The first inflection edge
energies in the Fe XANES, which is an indicator for iron oxidation state, for the 2Fe-Isu1
and 1Zn/2Fe-Isu1 samples were measured to occur at 7121.4 ± 0.1 and 7122.7 ± 1.3 eV
(Table 3), respectively, consistent with iron existing as Fe(II) in both samples; these
values are similar to those previously reported for Fe(II) bound to D37A or wt-Isu1.45, 54,
55

Analysis of the pre-edge 1s→3d electronic transitions in the Fe XANES, a feature that

can be used to confirm metal-ligand symmetry and also metal oxidation state, for the Feand Zn/Fe-Isu1 samples appear at similar maximum energies, and peak areas are
consistent with 6 coordinate octahedral Fe(II) model compounds in both samples (Figure
2.3B).124 However, addition of Zn to the Fe-Isu1 sample caused the 1s→3d transition
area to decrease by ca. 50%, consistent with a slight increase in Fe-ligand coordination
symmetry when zinc is added (Table 2.3). Analysis of the Zn XANES for the zinc-only
loaded (1Zn-Isu1) and the 1Zn/2Fe-Isu1 samples are identical, indicating the Zn(II)
coordination environment on Isu1 is unperturbed by Fe(II) binding. The Zn XANES edge
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max signal shows a duel nature suggesting metal is bound in a mixed Zn-S and Zn-O/N
ligand environment.125, 126 Finally, Fe XANES spectra used to test for differences in the
Fe and Zn loading sequence when forming 1Zn/2Fe-Isu1, provided in Figure 2.4, with
edge fitting analysis provided in Table 2.4, show there is no significant structural
difference from the perspective of the iron when Zn(II) is loaded prior to or after Fe(II) is
loaded onto Isu1.
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Figure 2.3. Normalized XANES for Fe- and Zn-Loaded Isu1. (A) Representative
spectra for Fe XANES for 2Fe-Isu1 (red) and 1Zn/2Fe-Isu1 (black). (B) Expended display
of the Fe-XANES pre-edge features for 2Fe-Isu1 (red) and 1Zn/2Fe-Isu1 (black). (C)
Representative Zn XANES for 1Zn-Isu1 (blue) and 1Zn/2Fe-Isu1 (black).
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Pre-Edge Area a

a

2Fe- Isu1

8.46 ± 2.94

Peak-First Inflection
Energy (eV)
7121.4 ± 0.1

1Zn/2Fe-Isu1

4.04 ± 1.34

7122.7 ± 1.3

Dimensionless area values.

Table 2.3. Analysis of Pre-edge and Edge First-Inflection Point Features from FeXANES for 2Fe-Isu1 and 1Zn/2Fe-Isu1. Pre-edge analysis of the 1s→3d transition in
Fe(II) Isu1 samples. Peak inflection values were calculated by taking the first derivate of
the edge feature for each.

48

Figure 2.4. Normalized Fe XANES for Zn/Fe Loaded Isu1 Samples Following a
Unique Sequential Loading Order (i.e., Fe then Zn loading, and Zn then Fe loading
of Isu1). All samples were eventually loaded with 1 equivalent zinc and 2 equivalents
iron, although the loading order was varied. (A) Fe-XANES for iron loaded first shown
above in purple while the Zn loaded first sample is shown in black. (B) Respective iron
pre-edge features are shown for iron loaded first (purple) and zinc loaded first (black).
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a

Pre-Edge Areaa

Peak Inflection (eV)

1Zn-2Fe-Isu1 (Zn loaded first)

4.04 ± 1.34

7122.7 ± 1.3

1Zn-2Fe-Isu1 (Fe loaded first)

3.67

7121.5

Dimensionless area values.

Table 2.4. Fe XANES Pre-edge Area and eV Inflection Analysis from Varying the
Fe/Zn Addition Order. Pre-edge areas of the 1s-3d transition signal for Fe(II) within
samples measured in dimensionless values.55 Peak inflection energy values were
calculated as the edge first derivate of the edge.
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Simulations of the X-ray absorption fine structure (EXAFS) region of the XAS
spectrum provides direct metrical characteristics for ligands coordinated to metals
bound to a metalloprotein.127 The Fourier transform (FT) of the EXAFS provides a
visualization of the pseudo radial distribution for the metal-ligand coordination
environment. Fe and Zn EXAFS analysis were used to characterize the metal site
structure for Isu1 when metals are coordinated separately and in combination. The FeEXAFS spectra for 2Fe-Isu1 and 1Zn/2Fe-Isu1, and their subsequent FT spectra, are
presented in Figure 2.5 (A, B, C & D). The single large feature in the FT suggests a
highly symmetric metal-ligand coordination environment for Fe(II) in both samples
(Figure 2.5 B and D). Simulations of the Fe-EXAFS for 2Fe-Isu1 suggests iron is
coordinated completely by oxygen and nitrogen-based ligands, with ca. 5 ligands
centered at an average Fe-O/N bond length of 2.19 Å and an additional nearestneighbor Fe-O/N ligand centered at 2.04 Å; long-range Fe•••C scattering is also
observed at distances of 3.16 Å and 4.17 Å (Table 2.5). Simulations of the Fe-EXAFS
for 1Zn/2Fe-Isu1 are only consistent only a single resolvable ca. 5 to 6 coordinate FeO/N ligand environment centered at an average bond-length of 2.13 Å; long-range
Fe•••C scattering is observed in this sample at 3.15 Å and 4.18 Å. The high DebyeWaller factor, a measure of the metal-ligand bond disorder, in the fit for the Fe-O/N
environment in the 1Zn/2Fe-Isu1 sample suggests a change in the symmetry of the Fenearest neighbor ligands for the samples compared to 2Fe-Isu1, however attempts to
deconvolute two possible distinct nearest neighbor environments for the 1Zn/2Fe-Isu1
sample failed, due to the spectral resolution of 0.13 Å for the data, likely indicating a
condensation of the two ligand environments in the Fe only sample moved to a more
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organized Fe-ligand environment when Zn is added.127 Bond lengths from the iron
nearest neighbor ligand environments in both samples are consistent with distances
reported for six coordinate Fe(II)-O/N models within the Cambridge Structural
Database.128
Analysis of the Zn-Isu1 EXAFS in the absence (1Zn-Isu1) and presence of
iron(1Zn/2Fe-Isu1) was used to characterize ligand metrical parameters for zinc bound to
the protein, as well as to determine if the zinc structure is perturbed upon addition of iron.
The Zn EXAFS for Zn-Isu1 and 1Zn/2Fe-Isu1 are shown in Figure 2.5 (panels E and G,
respectively). The Fourier transforms of the Zn EXAFS in both samples show a nearest
neighbor ligand pattern signal split into two independent environments (Figure 2.5 F and
H, respectively). Simulations of the Zn EXAFS in both samples suggests a 4 coordinate
Zn system with ca 2 oxygen/nitrogen ligands centered at 2.00 Å and ca. 2 sulfur ligands
centered at 2.30 Å. Debye-Waller (DW) factor values from simulations to the Zn-O/N and
Zn-S nearest neighbor environments in both samples are very similar, indicating only
minimal changes in the Zn-ligand bond disorder when Fe(II) is either present or absent.
Bond lengths from Zn-O/N and Zn-S ligand average bond values in both samples are
similar to those reported for 4 coordinate Zn-N2S2 models compounds (2.07 Å and 2.26
Å, respectively) published within the Cambridge Structural Database.128 Finally, in both
samples, long-range Zn•••C scattering is observed at ca. 3.12 and 4.06 Å.
To compare iron coordination environments across orthologs, iron loaded Hs, Dm,
Sc and Tm scaffold samples were prepared and characterized by Fe XAS along under
identical conditions with only a single Fe(II) atom loaded onto each protein. Full Fe EXAFS
and Fourier transforms for the iron loaded orthologs are presented in Figure 2.6.
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Similarities in the Fourier transforms of the Fe-EXAFS between all samples suggest a
conserved Fe-nearest neighbor ligand environment constructed by a ligand environment
centered aa t bond length of ca. 2.1 Å (displayed R +∆ is at 1.7Å), as shown in Figure
2.6B, D, F & H. Simulations of the EXAFS for the iron atom coordinated to yeast, human
and fly scaffold orthologs suggest an overall 6 coordinate Fe-nearest-neighbor ligand
environment constructed by two resolvable Fe-O/N ligand sets centered at an average
bond length between 1.99 and 2.01 Å and the second between 2.14 and 2.15 Å (Table
2.5); the ligand set composition between these three samples is similar. The Fe-nearest
neighbor coordination environment for the bacterial scaffold ortholog is more symmetric
based on the fitting analysis, with only a single six coordinate Fe-nearest neighbor ligand
environment constructed only by oxygen and nitrogen ligands, centered at 2.13 Å
observed. Long-range Fe•••C scattering is observed in all 4 samples, suggesting a
complex backscattering pattern due to the carbon atoms attached to coordinating ligand
atoms that exist as part of the amino acid side chain extensions; the presence of these
features confirm metal is bound to the protein and not adventitious. Sulfur scattering was
not observed for iron in any of the scaffold samples, consistent with our previous
reports.45, 54 Finally, there is a subtle shift in the Fe-O/N bond lengths reported for 1FeIsu1 (Table 2.6) vs. 2Fe-Isu1 (Table 2.5), possibly suggesting the first iron atom that
coordinates to Isu1 binds in a slightly different orientation; this would be consistent with
the two binding affinities measured for Isu1 Fe binding observed within our competition
assay. However, these differences between the one or two Fe(II) loaded Isu1 samples
are at the limits of the uncertainty for the technique so may be an artifact of the technique.
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Figure 2.5: Raw EXAFS, Fourier Transforms of EXAFS and Spectral Simulations for
Fe- and Zn-Isu1. Full Fe EXAFS for 2Fe-Isu1 and 1Zn/2Fe-Isu1 are shown in (A) and
(C), respectively. Full Zn EXAFS for 1Zn-Isu1 and 1Zn/2Fe-Isu1 are shown in (E) and
(G), respectively. Fourier transforms for the Fe EXAFS 2Fe-Isu1 and 1Zn/2Fe-Isu1 are
shown in (B) and (D), respectively. Fourier transforms for the Zn EXAFS for 1Zn-Isu1 and
1Zn/2Fe-Isu1 are shown in (F) and (H), respectively. Raw data is shown in black while
the best-fit simulations for each data set are shown in green.
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Sample

Nearest-Neighbor Ligand

Long-Range Ligand

Environment a

Environment a

Atom b

R(Å) c

C.N. d

s2 e

Atom b

R(Å) c

C.N. d

s2 e

F’ f

O/N

2.04

1.0

1.07

C

3.16

2.0

2.81

0.15

O/N

2.19

5.0

3.42

C

4.17

4.0

5.22

O/N

2.13

5.0

5.18

C

3.15

2.0

4.78

C

4.18

4.0

2.60

Fe EXAFS
2Fe-Isu1

1Zn/2Fe-Isu1

0.31

Zn EXAFS
1Zn-Isu1

1Zn/2Fe-Isu1

O/N

2.00

2.0

5.20

C

3.12

1.0

1.78

S

2.30

2.0

3.41

C

4.06

2.0

5.82

O/N

2.00

2.0

4.66

C

3.13

2.0

5.56

S

2.30

2.0

3.40

C

4.07

2.0

3.02

0.29

0.47

a

Independent metal-ligand scattering environment.
Scattering atoms: N (nitrogen), O (oxygen), C (carbon), S (sulfur).
c
Average metal-ligand bond length (+/-) 0.12 Å-1.
d
Average metal-ligand coordination number (+/-) 1.0.
e
Average Debye-Waller factor (Å x 103).
f
Number of degrees of freedom weighted mean square deviation between data and fit.
b

Table 2.5: Summary of Fe and Zn EXAFS Best Fit Simulation Parameters for Metal
Loaded Isu1. EXAFS data were simulated over the k-range of 1.0 to 13.0 k-1.
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Figure 2.6. EXAFS, Fourier Transforms of EXAFS and Spectral Simulations for FeLoaded Isu1 orthologs. Fe-EXAFS spectra and Fourier transforms of the Fe-EXAFS are
shown respectively for a single iron atom bound to the following Isu1 orthologs: H.
sapiens (panels A and B), D. melanogaster (panels C and D), S. cerevisiae (panels E and
F) and T. maritima (panels G and H). Raw data is shown in black while simulated data
is shown in green.
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Nearest-Neighbor Ligand

Long-Range Ligand

Environment a

Environment a

Sample

Atom b

R(Å) c

C.N. d

s2 e

Atom b

R(Å) c

C.N. d

s2 e

F’ f

S. cerevisiae

O/N

2.01

1.0

3.78

C

3.01

1.5

1.14

0.99

O/N

2.14

4.5

2.94

C

4.13

3.0

4.77

O/N

2.01

1.5

2.02

C

3.13

3.0

5.83

O/N

2.14

4.0

1.28

C

3.53

1.0

1.00

C

4.13

6.5

5.95

C

3.13

1.5

1.14

0.99

C

3.10

3.0

1.56

0.99

C

3.27

4.5

1.20

C

3.49

4.5

1.66

C

3.71

3.5

3.90

H. sapiens

D. melanogaster

T. maritima

O/N

1.99

3.0

3.78

O/N

2.15

2.0

2.94

O/N

2.13

6.0

4.30

0.45

a

Independent metal-ligand scattering environment.
Scattering atoms: N (nitrogen), O (oxygen), C (carbon), S (sulfur).
c
Average metal-ligand bond length (+/-) 0.12 Å-1.
d
Average metal-ligand coordination number (+/-) 1.0.
e
Average Debye-Waller factor (Å x 103).
f
Number of degrees of freedom weighted mean square deviation between data and fit.
b

Table 2.6 Summary of Isu1 Ortholog Fe-EXAFS Simulation Best Fit Parameters.
Spectra were fit over a k-range of 1.0 to 13.0 k-1.
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2.3.4 Mössbauer Spectroscopy of 57Fe-treated Isu1
Mössbauer Spectroscopy was used to characterize the electronic and magnetic
properties of iron bound to Isu1.
independent samples of
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Low-temperature and low-field spectra for two

Fe(II)-treated Isu1 are provided in Figure 2.7, A and B. Both

exhibited a nested pair of quadrupole doublets with parameters typical of Fe(II)
coordinated by 5-6 O/N donor ligands. The relative intensity of the inner:outer sites were
42:58 in the spectrum of the first sample and 49:51 for the second sample (Table 6).
Isomer shift and quadrupole splitting values for the inner doublet were ca. d = 1.26 mm/s
and DEQ = 2.22 mm/s for the first sample and d = 1.24 mm/s and DEQ = 2.11 mm/s for the
second. Corresponding parameters for the outer site were ca. d = 1.27 mm/s and DEQ =
3.05 mm/s for the first sample and d = 1.28 mm/s and DEQ = 2.95 mm/s for the second.
We believe these two sites correspond to the same iron sites observed in the XAS data
outlined above.
To evaluate whether the added
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Fe(II) was coordinated to the protein, both

samples were passed down an anaerobic size-exclusion chromatography column. The
eluate was monitored at 280 nm and passed directly to an inline ICP-MS for iron and zinc
detection. The chromatographic results for the first sample, which was isolated following
the standardized protocol outlined (Figure 2.7 C) revealed three Fe peaks, two Zn peaks,
and 4 peaks in the A280 protein spectrum. The first Fe and Zn species eluted at the same
position as a higher size protein species, occurring at nearly the void volume of the
column (V0 » 14.8 mL), suggesting a mass > 20,000 Da, consistent with a metal loaded
Isu1 dimer. The second Fe/Zn species eluted with a protein species at ca. 4 mL beyond
the void volume, suggesting a mass of ca. 15,000 Da, consistent with a metal loaded Isu1
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monomer. In the case of both metals, the intensity of the higher size species is much
more pronounced that that seen for the lower size (higher elution volume) species,
indicating most of the metal in these samples was attached to the larger molecular weight
mass protein species. The first sample also exhibited a strong A280 peak at elution
volumes of ca. 37 mL, which lacked both iron and zinc. Finally, at an even greater elution
volume, corresponding to a mass of ca. 350 Da, an iron peak was detected which
represented ca. 15% of the overall iron intensity. The peak was not associated with A280
or with any zinc peak. Given this and the estimated mass of the iron complex, we assign
this peak to a low-molecular-mass Fe species not associated with to protein, indicating
the same percentage seen in the Mössbauer intensity (ca. 15%) for the first sample was
not due to Isu1-bound iron.
The LC-ICP-MS chromatogram for the second sample (Figure 2.7d), which was
prepared following heavy dialysis with 100 mM EDTA in an attempt to remove all metal
from the sample. This A280 spectrum exhibited a broad peak in the region where Isu1
would be expected to migrate. A single intense iron peak was also observed in this same
region but it was also broadened relative to that seen in the first sample. Two Zn peaks
were observed, as in the first sample, but they were also broader. This suggests greater
heterogeneity in this particular sample. Another important difference is the presence of
intense iron peaks in the low-molecular-mass region, representing ~ 2/3rds of the iron in
the sample, with a lower percentage of zinc in the sample also occurring in similar regions
of elution. Based on this, we conclude in the second sample that only about 30% of the
iron present was bound to Isu1, the remaining likely bound to a small molecule
contaminant (likely EDTA) that was not completely removed during dialysis. This is
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congruent with the Mössbauer spectrum of the second sample (Figure 2.7b), which was
broader than the spectrum of the first sample, and less well resolved, but had similar
fitting parameters (Table 2.7).
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Figure 2.7. Mössbauer spectra and LC-ICP-MS of iron-treated Isu1. Upper panel:
Low-temperature low field (5 K, 0.05 T, parallel field) Mössbauer spectra of purified Isu1
with 0.95 equivalents of 57Fe (II) ascorbate added for 30 min in an anaerobic glove box.
Red lines indicate composite simulations assuming parameters and percentages given in
Table 2.7. Spectra a and b represent 2 independent samples. After spectra were
collected, each sample was thawed in a glove box, and chromatographed as described
in METHODS, affording chromatograms c and d, respectively. Black lines, absorbance at
280 nm; green lines, 57Fe detection; blue line, 66Zn detection. Intensities have been
adjusted relative to the sensitivity of the detector (Zn traces were multiplied by 4 to
improve visualization) for direct comparison.
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δ (mm/sec) a

ΔEq (mm/sec) b

Fig. 6a: Inner Doublet
Outer Doublet

1.26
1.27

2.22
3.05

0.55
0.47

42%
58%

Fig. 6b: Inner Doublet
Outer Doublet

1.24
1.28

2.11
2.95

0.57
0.54

49%
51%

H. sapiens

1.26

2.60

0.768

100%

D. melanogaster

1.24

2.83

0.801

100%

T. maritima

1.26

2.61

0.742

100%

FeH20N2O14S2 (aq)

1.35

3.06

Sample

Lw (mm/sec) c Percent Area

S. cerevisiae

100%

a

δ – Isomer shift
ΔEq – Electric quadrupole
c
Lw – line width at full width half maximum of signal
b

Table 2.7. Summary of Mössbauer Simulations for 57Fe-Loaded Isu1 Orthologs.
Spectra simulated are displayed in Figure 2.7 (S. cerevisiae) and Figure 2.8 (for H.
sapien, D. melanogaster, T. maritima and solubilized ammonium ferrous sulfate
hexahydrate).
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For a comparison of the iron sites between the scaffold orthologs, Mössbauer
spectra were measured for a single
scaffold orthologs (Figure 2.8).
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Fe bound to the yeast, human, fly and bacterial

The average isomer shift and quadrupole splitting

obtained for the human, fly and bacterial spectra were d = 1.25 ± 0.02 mm/s and DEQ =
2.7 ± 0.1 mm/s, similar to values obtained for the

57

Fe-Isu1 samples. Although the

signal/noise ratio in these four comparison spectra are not optimal, each spectrum
exhibited similar high-spin Fe(II) features similar to those observed in the high resolution
data collected for the first sample of Fe-Isu1 (displayed in Figure 2.7A), suggesting similar
iron environment in all of the scaffold orthologs.
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Figure 2.8. Mössbauer Spectra of Isu1 Orthologs. Offset for clarity, from top to bottom:
S. cerevisiae Isu1 4.5K 700G m parallel field, H. sapiens ISCU 100K 700G parallel field,
D. melanogaster Isu 4.5K 400G parallel field, T. maritima IscU 4.5K 400G applied field.
All samples have been collected ~24h for about 3 - 4 M counts of radiation.
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2.3.5 Cluster Assembly Assay with Zn-Loaded Isu1
To clarify the impact zinc binding has on the ability of Isu1 to perform Fe-S cluster
assembly, we screened the impact this metal has on the yeast NIaUF (complex with yeast
Nfs1, Isu1, Isd11, Yfh1 and bacterial Acp) activity using our cluster assembly protocol.55
The Fe-S cluster assembly activity was measured in the presence and absence of Zn. In
the absence of zinc, the yeast NIaUF complex rapidly makes Fe-S clusters when provided
with both aqueous L-Cys and Fe(II) as substrates (Figure 2.9); cluster assembly was
measured by the increase in intensity of the 2Fe-2S cluster specific 430 nm CD spectral
signal.47, 55 Following addition of a stoichiometric amount of Zn first loaded onto Isu1 prior
to NIaUF complex assembly, Fe-S cluster assembly activity was dramatically reduced (to
ca. 10% of uninhibited as seen in the absence of Zn), indicating zinc significantly inhibits
cluster assembly by the yeast NIaUF complex. Interestingly, a previous report using the
human NIaU complex indicated complete inhibition of cysteine desulfurase activity by Zn,
which could be reversed upon addition of frataxin.57 Here we measure only Fe-S cluster
assembly, and out data shows the impact of Zn on inhibiting the entire pathway is
dramatic even in the presence of yeast frataxin.
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Figure 2.9. Fe-S cluster assembly assay. Cluster assembly assay detected by Circular
Dichroism Spectroscopy at 430 nm using NIA, Yfh1, Fe(II), L-Cys, DTT and either with
apo-Isu1 (blue) or Zn-Isu1 (black).

66
2.3.6 Sequence Alignment of Isu1 Orthologs
The amino acid sequence alignment for the yeast, fly, human and bacterial
scaffolds are given in Figure 2.10 for comparison of conserved residues the might help
illuminate which regions of the scaffold are used for iron binding at a potential site distinct
from the Cys rich active site. There is a high overall sequence homology between
orthologs (ca. 94%, 99% and 90% between Sc and the Hs, Dm and Tm orthologs,
respectively) and also a high sequence identity (67% and 61% between Sc and Hs and
Dm, respectively) for the eukaryotic proteins. The sequence identity between the yeast
and the prokaryotic sample is rather low (23% between Sc and Tm). The three conserved
active site cysteine residues (Isu1 residues Cys69, Cys96, Cys139) are highlighted in
pink, the conserved active site aspartic acid (Isu1 residue Asp71) is highlighted in yellow,
and the histidine residue conserved in eukaryotes also at the active site (Isu1 residue
His138) is highlighted in orange within Figure 2.10. All these identified residues play key
roles in scaffold Fe-S cluster assembly and constitute residues at the Zn binding sites in
the human through bacterial scaffolds42,

56, 105, 106

Met141, shown in red as the Isu1

suppressor mutant identified by the Dancis Lab (U Penn) that confers cluster assembly
activity in yeast under frataxin depleted conditions,129 is in close proximity to the Isu1
residue Cys138. Folding in the C-terminal helical region where this methionine is located
is variable within different scaffold structures depending on Zn or Fe-S cluster loading at
the active site,130 suggesting dynamic transitions of structure in this region may play a
role in metal delivery and/or Fe-S cluster assembly and release. Conserved residues
observed in the primary sequence of ortholog family members that may contribute to an
initial iron binding site unique can be identified through conservation of the acidic residues
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and also conserved histidines. Specific residues that have high sequence identity based
using the Isu1 numbering scheme include: Glu42, Asp53, Asp81, Asp89, Glu108,
Asp116/Asp117, and Glu129; each residue is conserved across both Prokaryotes and
Eukaryotes.
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Figure 2.10 Sequence Alignment of Isu1 Orthologs. Mature protein sequences from
H. sapiens, D. melanogaster, S. cerevisiae and T. maritima. Identical residues are shown
in blue and conserved/semi conserved residues are shown in green. Conserved 3-Cys
active site consists of C69, C96, and C139 (magenta) and D71 (yellow) or H138 (orange)
according to the consensus ruler. The methionine conserved only in Eukaryotes (M141)
is highlighted in red.
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2.3.7 Modeling of Zn-Isu1 Metal Site Structure
Since the Isu1 structure has not been solved, we modeled the structure of Zn-Isu1
and compared it to previously published Zn-bound ortholog structures.42, 106 The NCBI
sequence for Isu1 was used to predict the protein’s structure.118, 122 The Isu1 Zn-site
structure was energy minimized and the overall modelled structure was compared to
known PDB crystallographic structures.122 Based on the modeled structure, shown in
Figure 2.11, the single Zn atom binds to the Isu1 Fe-S cluster assembly active site using
a subgroup of the conserved cysteine residues including Cys69, Cys96 and Cys139. In
this calculated structure, acidic residue Asp71 is positioned to provide additional O/N
ligands to the bound metal, while a slight unfolding of the C-terminal helix would be
required for His138 to participate as a ligand to coordinated Zn.

70

Figure 2.11. Model of Zn and Fe association to Isu1. Expressed recombinant Isu1
treated with EDTA is metal free and adopts the “disordered” structure at the active site.
Zn(II) binds to active site cysteine residues resulting in a structured conformation. ApoIsu1 can also bind Fe(II) however Fe-Isu1 still exists in the disordered conformation. Iron
can bind in the absence or presence of Zn, however Zn-Isu1 is unable to generate a FeS cluster. Following Fe(II) delivery, coordinated with association to the NIA complex and
the delivery of persulfide, a Fe-S cluster is formed onto the NIAU complex in a frataxin
dependent manner.
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2.4 DISCUSSION
2.4.1 Comparison of Iron binding by Isu1
Iron binding by the scaffold protein in an initial step during mitochondrial Fe-S
cluster biosynthesis,56,57 and here we report Isu1 binds two iron atoms for Fe-S cluster
assembly assay at µM Fe(II) binding affinities. This current and recent report utilized a
competition Fe(II) binding assay to provide an enhanced measurement for protein metal
affinity in an environment that closer represents conditions observed in vivo.31 As shown
previously, iron associated to Isu1 is stable as high-spin symmetric 6 coordinate Fe(II)
coordinated by only oxygen and nitrogen based protein ligands. The impact of this
binding architecture, shown in this report to be conserved across both prokaryotic and
eukaryotic orthologs, is that the scaffold must bind iron initially at a site distinct from the
protein’s sulfur ligand rich active site used for Fe-S cluster assembly. This report also
shows by CD that Fe(II) binds to the disordered form of the Isu1’s structured state. Finally,
LC-ICP-MS analysis for our first sample indicates Fe(II) loaded Isu1 is at a higher
concentration as a stable protein homodimer. The dimerization properties of several
homogeneous scaffold orthologs are well established,131 however the human scaffold,
when part of the NIAU complex, binds ISCU as a monomer.42, 49, 101, 107 While binding of
scaffold to cysteine desulfurase forms a stable complex in the absence of metal, 48, 107, 132
early yeast pulldown analysis indicated Yfh1 as a primary binding partner to Isu1 in vivo,
91, 133

with Yfh1 binding to Isu1 in an iron dependent manner with a protein binding affinity

an order of magnitude tighter

45

than affinities reported for wt-human frataxin binding to

the apo-human NIAU complex.107 In addition, the dynamic behavior seen for scaffold
orthologs, either with regard to intramolecular

51, 52

or intermolecular protein flexibility,

55
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has been shown to support the scaffold when performing Fe-S cluster biosynthesis and
delivery. We therefore suggest that while the recent outstanding structural details
provided for the scaffold as it interacts within the NIAUF protein complex exist, these data
paint a single picture of the cluster assembly apparatus at one state, providing a snapshot
of intermolecular interactions within the assembly apparatus. Details including a Fe(II)
loaded Isu1 homodimer or a Fe(II)-loaded Isu1 as a heterodimer prior to Nfs1 coordination
may exist as a stable complex at some stage during the in vivo Fe-S cluster biosynthesis
reaction mechanism, and so should be considered.
Regardless of oligomeric state, Fe(II)-loaded Isu1 will readily produce Fe-S
clusters when it is part of the yeast NIaUF protein complex, assuming reductant and
activated sulfur as a substrate are also available.55 Previously we confirmed structurally
by XAS that Fe(II) bound to Isu1 at an initial oxygen and nitrogen based ligand site can
be used to directly produce a Fe-S clusters that have an iron•••iron distance at 2.7Å.45, 54
The relevance of this binding site is that metal must be diverted to the Isu1 Cys rich active
site for direct use during the Fe-S bioassembly. To better understand how metal is
shuttled intramolecularly to accomplish assembly, it will be important to identify Isu1
residues at the Fe(II) binding site. A comparison of the amino acid sequences between
scaffold orthologs suggests several potential Fe-binding residues on Isu1 that could serve
at the initial Fe binding site (most notably Isu1 residues Glu42, Asp53, Asp81, Asp89,
Glu108, Asp116/Asp117, and Glu129); mutagenesis experiments on Isu1 are underway
to better identify where ferrous ion bind to Isu1. Interestingly, one implication for the
scaffold having an initial Fe(II) binding site separate from the cluster assembly site could
be as a way to help orchestrate the coordinated delivery of both substrates
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simultaneously or in series to the cluster assembly site; if sulfur in the form of persulfide
is being delivered directly to a scaffold active site Cys residue through intermolecular
contact between Isu1 and Nfs1,97 the proximity around the Isu1 active site for use in
simultaneous Fe delivery would likely be too constrained for an additional biomolecule to
bind. However, scaffold structural transitions that could be induced to drive Fe delivery
and Fe-S cluster assembly could be triggered by protein partner association (i.e., Yah1
or Yfh1) post sulfur delivery, as recently suggested for the human system 107, and scaffold
folding my provide the energetics to promote Fe(II) intramolecular translocation driving
Fe(II) to the Isu1 active site. Ferrous ion loading onto an initial binding site appears to be
conserved on all scaffold orthologs, identification of the loading site will be important to
understand the assembly reaction mechanism.
2.4.2 Functional consequence and relevance of Zinc binding by Isu1
Zinc binding has been used to stabilize the fold if several scaffold orthologs
allowing for macromolecular structural determination.42, 52, 53, 56, 134 In this report, we show
a single Zn ion binds to the Isu1 active site with sub µM binding affinity (Kd = 0.44 µM), a
value that is an order of magnitude tighter Isu1’s Fe binding affinity; these comparative
affinity differences are not surprising, since Zn is predicted to bind more tightly by the
Irving-Williams series.135 Following our standard purification protocol, we show by ICPMS that as-isolated apo-Isu1 is consistently partially loaded with low levels of contaminant
zinc (ca. 0.2% Zn to protein stoichiometry), even after treatment with a strong chelator
like EDTA. With Isu1, care must be taken using high concentrations since EDTA itself
stays associated with the protein despite extensive dialysis and this can distort
spectroscopic analysis.

Our CD data confirms Zn drives Isu1 into its structured
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conformation, a transition observed in several scaffold orthologs.42,

48, 53, 56, 133

Our

structural analysis also confirms Zn ions bind to Isu1 in the manner similar to that reported
for Zn-loaded orthologs through direct coordination to active site Cys residues.57
Regarding Fe-S cluster assembly activity, Zn binding to Isu1, when part of the yeast
NIaUF complex, dramatically inhibits cluster biosynthesis even in the presence of frataxin.
Interestingly, it was recently shown that zinc binding to human ISCU inhibits cysteine
desulfurase activity for the human NIaU complex, however this inhibition is reduced when
frataxin was added.57 We believe both results are however consistent; in the human
report, while frataxin binding to the Zn-NIaU complex at the Zn-ISCU/NFS1 protein
interface liberates the NFS1 active site Cys from participating in Zn coordination and
allowing for cysteine desulfurase enzymatic activity, the Zn remains stably bound to ISCU
in their structure.107 Zinc bound at the ISCU active site will certainly be expected to inhibit
Fe-S assembly in a manner that we see using the yeast system in this study, however it
could be that differences exist between ortholog protein activity.
2.4.3 Zn and Fe bind to Isu1 at distinct sites
In this report, we explore the impact of Isu1 when binding both Zn and Fe ions as
a way to help further explore the physiological impact of Zn binding to the scaffold and to
further explore mechanistic details that may provide insight into iron delivery for the
scaffold. Since Zn-Isu1 binding drives the Fe-loaded scaffold into its structured
conformation, and Zn binds at the Isu1 active site in a manner likely similar to that seen
when the scaffold has a Fe-S cluster loaded, these combined data support a molecular
folding transition that is likely required to Fe from initial to assembly active site on the
scaffold. Analysis of the Fe XANES 1s→3d pre-edge feature in Fe-Isu1 indicates Zn
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binding enhances iron-ligand coordination symmetry for bound metal but its geometry or
direct ligands, indicating the Fe-loaded scaffold must still have dynamic flexibility in the
metal site structure before transfer to the active site occurs. In contrast, iron binding to
the Zn-loaded Isu1, in the structured state, does not alter the protein’s overall fold or
perturb the Zn bound structure, suggesting the structured state is a stable conformation.
Our LC-ICP-MS and XAS results suggest binding of one metal does not preclude binding
of the other metal to Isu1. Combined, these data suggest a model for Fe and Zn binding
at independent Isu1 sites on the protein, and while Zn binding favors/influences the
structured form of Isu1, it does so without preventing Fe binding (see model in Figure
2.12). However, on Zn free Isu1 when part of the NIaUF complex is active for Fe-S cluster
assembly, suggesting in the yeast system Zn inhibits the protein’s active site through
stable coordination.
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Figure 2.12 Model of Zn and Fe association to Isu1. Expressed recombinant Isu1
treated with EDTA is metal free and adopts the “disordered” structure at the active site.
Zn(II) binds to active site cysteine residues resulting in a structured conformation. ApoIsu1 can also bind Fe(II) however Fe-Isu1 still exists in the disordered conformation. Iron
can bind in the absence or presence of Zn, however Zn-Isu1 is unable to generate a FeS cluster. Following Fe(II) delivery, coordinated with association to the NIA complex and
the delivery of persulfide, a Fe-S cluster is formed onto the NIAU complex in a frataxin
dependent manner.
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There are still several questions that remain regarding the physiological relevance
or significance of Zn binding to scaffold. The biophysical impact of Zn loading onto Isu1’s
structure is clear; Zn stabilizes the structured conformation of the protein, driving the
equilibrium from disordered (D) to structured (S) protein conformation.51-53, 56 Zinc binding
is therefore obviously beneficial when one wants to study the structured form of the
scaffold ortholog. Assuming this D→S transition relates directly to conformational
changes observed during Fe-S cluster assembly, Zn loading also helps stabilize the
homogeneous structured form of the scaffold, hence allowing for biochemical analysis of
the structured ortholog to be completed. The fact that Zn and Fe bind simultaneously to
Isu1 at independent sites indicates Fe(II)-binding and the metal translocation from initial
to active site must be a process that occurs during assembly. In our in vitro studies, Zn
binding to Isu1, and its subsequent inhibition of the yeast NIaUF complex, is likely an
artifact of our growth and isolation conditions. However, it is possible that a role for Zn in
helping regulate ISC assembly under perturbed conditions in vivo exists. In E. coli, under
conditions of zinc toxicity, excess Zn ions disrupts Fe-S cluster biosynthesis by binding
irreversibly to IscU, indicating a direct influence for Zn binding and scaffold protein activity
under toxicity conditions.136 In addition, the competition of Zn and Fe-S clusters for
binding at similar sites indicates a close balance for selective metal placement needs to
be monitored during normal cell function.25 However, under normal conditions, it seems
counterproductive that nature would regulate the mitochondrial Fe-S cluster assembly in
cells using Zn, since in a natural environment the prevalence of available mitochondrial
Zn binding is high, so hard to regulate, and simple adventitious inhibition of Isu1 would
be counterproductive to the cells need for Fe-S cluster production
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CHAPTER 3: C-TERMINAL ALPHA HELIX OF ISU1 IS ESSENTIAL FOR
FE-S CLUSTER ASSEMBLY
3.0

PRELUDE
In recent years, multiple crystallographic studies have been published showing in

detail the assembly of the ISC complex. These studies, however, only represent a
moment in time and are unable to describe the nature of an entire protein complex. The
work described in this chapter aims to characterize regions on the scaffold protein, Isu1,
and suggest how these regions contribute to cluster assembly which have not been
previously described. In addition, this work has significant clinical relevance to a rare ISC
related disorder, ISCU myopathy.

This chapter is adapted from a recently written

manuscript which will be submitted to Protein Science sharing the title of this chapter. I
contributed most of the data and prepared the manuscript for this work with assistance
from Karl Koebke from our group who helped with some of the competition assay studies,
former graduate student Andria Rodrigues who started this project and Dr. Andrew Dancis
from UPenn who designed the truncation mutants. All contributing authors and institutions
for the manuscript are listed below:
Brianne E Lewis‡, Andria Rodrigues(?)‡, Karl Koebke‡, Andrew Dancis# and, Timothy L
Stemmler‡.
‡

Department of Pharmaceutical Science, Wayne State University, Detroit, MI 48201;

#

Department of Medicine, Division of Hematology-Oncology, Perelman School of

Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
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3.1 INTRODUCTION
Fe-S clusters are utilized ubiquitously in nature and found in every biochemical
pathway within roles that include electron transfer, chemical bond activation, iron sensing,
protein folding, etc. 80, 137 These Fe cofactors, primarily synthesized by the ISC assembly
pathway within the mitochondria of eukaryotes with a complementary pathway
operational within the cytosol, are loaded onto apo-metalloproteins during posttranslational modification events.138 Given their essential nature, it is not surprising that
mechanisms which direct their assembly are complex in their nature and tightly regulated.
Perturbations in cluster synthesis reduce cell viability, and this condition is directly linked
to several human diseases including Friedreich’s ataxia and ISCU myopathy. Friedreich’s
ataxia, a cardio- and neurodegenerative disease resulting from a GAA trinucleotide repeat
expansion in the Frataxin gene, results in a mitochondrial iron overload phenotype and a
reduction in cellular frataxin levels.64 Frataxin, which is nuclear encoded protein that
contains a mitochondrial targeting signal, is essential for eukaryotic mitochondrial Fe-S
cluster biosynthesis and a direct partner to the scaffold protein (Isu1 in yeast, ISCU in
humans) that performs the assembly of Fe-S clusters.65 ISCU myopathy is another
disease related to an inability to produce Fe-S clusters. A splice mutation in the ISCU
gene results in abnormal splicing and an introduction of a premature stop codon which
leads to decreased levels of the ISCU protein and early truncation of the protein’s Cterminal a-helix.139 As a result of these truncations, patients exhibit severe exercise
intolerance and myoglobinuria139, with cellular phenotypes that include a decrease in iron
regulatory protein (IRP1), succinate dehydrogenase and aconitase levels coupled with
iron accumulation in skeletal muscle.139, 140 Therefore, both Friedreich’s ataxia and ISCU
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myopathy are diseases related to disruption in iron homeostasis and mitochondrial Fe-S
cluster production and understanding the pathology of these disorders will require an
understanding of the Fe-S cluster assembly pathway at the molecular level.
Mitochondrial Fe-S cluster assembly in the mitochondria is driven by the
coordinated activities proteins that form the ISC cluster assembly complex.41, 42 At the
core of this complex in yeast is the Fe-S cluster assembly protein “Isu1”, the scaffold that
receives ferrous iron and sulfur in the form of persulfide to construct the Fe cofactors41-43,
45

. Isu1 interacts in yeast with the cysteine desulfurase “Nfs1” that provides sulfur as the

substrate, the accessory protein “Isd11”, the acetyl carrier protein “Acp1” and the frataxin
protein “Yfh1” to form the complex structural assembly seen in Figure 1.1.43 The human
scaffold “ISCU” active site (residues Cys 69, Cys95, Cys138) are in close proximity to the
conserved LPPVK residue region and the “alanine loop” (Ala66-Asp71) on the protein,
and these scaffold residues make contacts with b-sheets elements 1, 2 and 3 on human
frataxin “FXN”, with specific contacts with FXN residue W155.43 Located on human FXN

b-sheets 1 and 2 are acidic residues shown to be critical for the protein’s iron binding
activity across orthologs.44

The flexible loop on NFS1, containing the enzyme’s active

site cysteine (C381), is shown to make direct contact with ISCU at its active site,
supported in its structure by a Zn ion coordinated to the scaffold.42, 43
Despite the highly conserved nature of the C-terminal a-helix of scaffold orthologs,
there is little evidence regarding its significance to cluster assembly. Structural data
indicate that this helix is adjacent to the protein’s active site and could be required for
correct positioning of the active site for persulfide transfer and to stabilize the LPPVK
region at the frataxin-Isu1 interface.43 Reports on ISCU myopathy suggest the scaffold
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C-terminus plays a role in dimerization and stability of the protein complex.60, 139, 141 Given
the impact on cellular iron homeostasis and metabolic function of a truncated C-terminal
a-helix from ISCU myopathy, this region warrants investigation as it relates to cluster
assembly. In this report, we created three truncated Isu1 mutants (Isu1 ∆10, ∆17, ∆22)
to explore ISCU myopathy in vitro. Sequence alignment for each mutant is shown in
Figure 3.1A in comparison to full length wild type Isu1 and skeletal muscle ISCU (ISCUSM), the sequence from ISCU myopathy.139 Position of the C-terminus and length of the
truncations can be seen in Figure 3.2B related to the protein’s active site and LPPVK
domain. Each truncation mutant retains all three active site cysteine residues. Isu1∆22
is truncated after A143. Isu1∆17 retains acidic residues D144 and E145 and is truncated
after K148. Most significantly, Isu1∆10 is truncated to a similar length as ISCU-SM. We
will explore the consequence of a truncated C-terminus to isolate its structural
significance from a series of mutations present by ISCU myopathy. Our results indicate
that the C-terminus of Isu1 is critical for Fe-S cluster assembly.
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Figure 3.1 Sequence Alignment of Isu1 C-terminal truncations. Mature protein
sequences from S. cerevisiae Isu1 and truncations are shown (A). Number of residues
truncated from the C-terminus are noted by ∆#. Modeled Isu1 structure (B). Isu1,
Isu1∆10, Isu1∆17 and Isu1∆122 truncation residues are located on the C-terminal ahelix. Residues included on each truncation are highlighted on the C-terminus and
correspond to the color sequence in (A); Isu1 (black), Isu1∆10 (blue), Isu1∆17 (red) and
Isu1∆22 (purple). Fe-S active site cysteine residues (C69, C96, C139) are shown in
yellow with LPPVK domain (cyan). Isu1 structure modeled using I-Tasser server.117, 118
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3.2 METHODS & MATERIALS
3.2.1 Sc Isu1 and Isu1 Truncations Expression and Purification
The wild type Isu1 (S. cerevisiae) and truncation mutant (∆10, Isu1 ∆17, and Isu1
∆22) genes were transformed into C41(DE3) cells and incorporated into a pET21b-mIsu1
plasmid for use in protein expression (Lucigen) in a manner outlined previously 45, 54. Cells
were grown with Ampicillin (0.1 µg/µL) in Luria-Bertani broth at 37°C and shaken at 250
rpm. At an OD600 of 0.6, cells were induced with a final concentration of 0.8 mM IPTG.
Following induction, cells were grown for an additional 3 hr and harvested by
centrifugation at 8000 rpm for 20 min at 4˚C. Cells were stored at -80˚C until lysing. All
isolation steps were performed at 4˚C following a previously published protocol but
outlined below.54, 55 Frozen cells were resuspended in 50 mM NaPO4, 300 mM NaCl, 20
mM Imidazole and 5 mM b-Me (binding buffer, pH 7.5) in the presence of a Complete
EDTA free Protease inhibitor cocktail tablet (Roche). Cells were lysed by three passes
through an Emulsaflex, followed by centrifugation at 21,000 rpm for 60 min.55 Crude
fractions were filtered first through a 0.4 µm and then 0.2 µm sterile filter. Soluble
fractions were loaded onto a 5 mL His-Trap purification column (GE Healthcare) preequilibrated with binding buffer. Protein was eluted using an imidazole gradient (between
20 - 500 mM). Isu1 fractions were pooled, concentrated and dialyzed (2 buffer exchanges
for 3 hr each in 2L volume) against 20 mM HEPES, 300 mM NaCl, 10 mM EDTA and 5
mM b-Me (pH 7.5) buffer. Dialyzed samples were passed through a Sephadex 75 size
exclusion column (GE) equilibrated with 20 mM HEPES, 300 mM NaCl, 10 mM EDTA
and 5 mM b-Me (pH 7.5). Isu1 typically eluted from the column as a single species at
>95% purity, as judged by a single A280 peak in the chromatograph, and from the SDS-
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page gel analysis using a 4-20% polyacrylamide gel.45 Isu1 and all truncations eluted
from the S75 column between 55-60 mL. Metal chelation protocol by EDTA treatment
was determined to be effective (<0.2% contaminant) based on previous ICP-MS analysis
of Isu1 samples.
3.2.2 Circular dichroism of Isu1 compared to truncations
Isu1 and truncation samples were characterized for secondary structure using a
Jasco 1500 spectrophotometer as described previously.55 Samples were collected using
a 0.1 cm quartz cuvette at 27˚C. Protein samples were prepared at 10 µM in 5mM NaPO4
buffer at pH 7.5. For reproducibility, an average of thirty scans were collected from three
independent purified protein samples and averaged together for final analysis. Before
spectral collection, a baseline at each wavelength was subtracted to eliminate buffer
signal. Data were analyzed using the Jasco CD Pro analysis software and simulated
using the CONTIN method using the SP29, SP37, SP43, SMP50 and SMP56 reference
sets.111 Values obtained from simulations using each database were averaged to obtain
final analysis parameters.
3.2.3 Fe Protein Binding Competition Assay
Iron and binding affinities to Isu1 and truncations were determined according to
our recently reported competition assay using Mag-Fura-2 (Molecular Probes) as our
metal chelator.54, 120 As previously outlined, Mag-Fura-2 forms a 1:1 complex with the
divalent cations Fe and Zn, displaying a maximum absorbance at 325 nm when either
metal is bound and a feature at 366 nm in its apo state.54, 55 The reduction of absorbance
at 366 nm during metal loading was measured using a Shimadzu UV-1800
spectrophotometer housed in a Coy wet anaerobic chamber. Titration data for adding a
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divalent metal ion into the protein/mag-fura-2 mixture were collected anaerobically at
room temperature using a 1 cm quartz cuvette. All samples were prepared anaerobically
in 20 mM HEPES, 300 mM NaCl and 5 mM TCEP (pH 7.5) buffer.
Samples were prepared for analysis in the following manner. All reagents/buffers
were Ar(g) purged and equilibrated overnight within a Coy anaerobic wet chamber prior
to experimentation. Metal and apo protein solution samples were prepared immediately
before use under the same buffer and anaerobic conditions. Three independent protein
samples, incubated in 5 mM TCEP prior to titrations, were dialyzed using anaerobic buffer
before analysis to remove the TCEP. Full length Isu1 was run with each truncation on
the same day as a control. Mag-fura-2 concentrations were varied between 0 and 8 µM,
while the protein concentration was held constant at 4 µM for each run. A solution of 2.0
mM ammonium ferrous sulfate hexahydrate (Sigma) prepared in our anaerobic running
buffer listed previously was added in progressive increments until saturation was reached.
After each addition of aqueous ferrous ions, an absorption spectrum was collected
between 200 - 800 nm. Initial apo mag-fura-2 concentrations were determined using the
molar absorptivity (e) value of 29,900 M-1cm-1 for the compound, measured at the
wavelength of 366 nm.54 The absorbance at 366 nm, corrected for dilution, was then
used to calculate binding parameters. Binding data were simulated with the program
DYNAFIT110, using a non-linear least squares analysis script to identify the binding
capacity and metal stoichiometry in a manner previously outlined.54, 55 Each titration
experiment was simulated using both one and two-site metal binding models.
3.2.4 X-ray Absorption Spectroscopy for Fe loaded Isu1 and truncations
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Metal loaded protein XAS samples were prepared anaerobically in our Coy
anaerobic chamber using solution samples that had been initially degassed by dialysis
(protein) or by dissolving (metal salt samples) within anaerobic buffer and then stored at
4°C under an Ar(g) atmosphere. XAS samples were prepared at > 500 µM final protein
concentration in 20 mM HEPES (pH 7.0), 300 mM NaCl and 5 mM β-Me buffer. Initial
XAS spectra for all Isu1 proteins were collected at the Stanford Synchrotron Radiation
Lightsource (SSRL) on beamline 7-3. Duplicate independent samples were collected at
SSRL on beamline 9-3. Each Isu1 sample was loaded with 1.9 equivalents of Fe(II) from
an ammonium ferrous sulfate hexahydrate solution. All XAS samples were diluted by
addition to 30% glycerol to the sample as a glassing agent, then loaded into XAS Lucite
sample cells wrapped with Kapton tape, flash frozen in liquid nitrogen, removed from the
glove box and finally stored in liquid nitrogen until data collection. SSRL beamlines 7-3
and 9-3 were equipped with a Si[220] double-crystal monochromators containing focusing
mirrors for harmonic rejection. Fluorescence spectra were collected using a Canberra
100-element (beamline 9-3) or a 30-element (beamline 7-3) Ge solid state detector for
fluorescence measurements. During data collection, samples were maintained at 10 K
using an Oxford Instruments continuous flow liquid helium cryostat at both SSRL
beamlines and at ca. 24 K using a helium Displex Cryostat at NSLS. Beamline 9-3 iron
data were collected with a 6 µm Mn filter placed between the cryostat and the detector to
reduce unassociated scattering for the Fe XAS. For all beamlines, an Fe foil spectrum
were collected simultaneously with each protein spectrum for spectral energy calibration.
All XAS spectra were recorded using 5 eV steps within the pre-edge region, 0.25 eV steps
within the edge region and 0.05 Å-1 increments within the extended X-ray absorption fine
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structure (EXAFS) region. Data were collected out to k = 13 Å-1 for both elements,
integrating from 1 to 25 s in a k3-weighted manner. An average of 6 to 10 scans were
collected on each sample and these were averaged for overall analysis. Each scan lasted
approximately 40 minutes. Each spectrum was closely monitored for X-ray induced
radiation damage.
XAS spectra were processed and analyzed using the EXAFSPAK program suite
written for Macintosh OS X 112. Fluorescence scans corresponding to each channel were
examined for anomalies. A Gaussian function was fit to the pre-edge region and a cubic
spline was fit to the EXAFS region of the data for baseline subtraction. Spectra were
simulated using single and multiple scattering amplitude and phase functions generated
using the Feff v7.2 (7-3) and v8.0 (for 9-3 data) software packages; the Feff programs
were integrated directly within EXAFSPAK software.113 Calibrated scale factors (Sc) and
energy shift E0 values were held static during simulations, using the dimensionless Sc
value of 0.95. Calibrations of the theoretical scale factors and energy shift values were
obtained by fitting crystallographically characterized compounds to provide the Sc and E0
values utilized during protein data simulations.44

E0 values for protein Fe-O/N/C

simulations were set at -11.5 eV.44 All Fe EXAFS data were fit using a k range of 1 to
13.0. EXAFS spectra were simulated using both filtered and unfiltered data, but only
simulations of unfiltered data are presented. Simulation protocols and criteria for
determining the best fit to the empirical data have been described previously.44
3.2.5 [2Fe-2S] Cluster Assembly Assay
Fe-S cluster assembly was measured via. our cluster loading assay onto Isu1 and
truncations following a previously published protocol.55 All solutions, reagents and protein
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samples were degassed with Ar(g) buffer by dialysis, and stored on ice within our Coy
anaerobic chamber for use in the assay. The reaction buffer used during assembly
contained 20 mM HEPES and 300 mM NaCl (pH 7.5). Reagents and apo Isu1 samples
were mixed within the Coy anaerobic chamber in the following amounts to initiate cluster
formation: 10 µM Nfs-Isd11 complex, 50 µM Isu1, 10 µM Yfh1, 500 µM L-Cys, 5 mM DTT
and 75 µM Fe(II)(aq). Fe-S cluster assembly was first monitored for the full length Isu1
protein as a positive control followed by each truncation. After the addition of Fe(II),
samples were placed in a 1 cm pathlength sealed cuvette and the cuvette was then
quickly transferred to the Jasco-1500 Spectrophotometer for data collection (with an
average of a 30 second dead time during transfer). CD spectra were measured at 430
nm for 60 minutes to monitor cluster formation activity in a manner previously reported.55
Data were averaged from the 3 independent measurements each completed on protein
isolated from 3 different isolation preps.

3.3 RESULTS & DISCUSSION
3.3.1 Stability of Isu1 constructs by Circular Dichroism
Full length Isu1 and truncated forms of the protein were characterized for
secondary structure composition using Circular Dichroism (CD) spectroscopy; the goal
was to determine if truncation of the C-terminal helix of the protein result in a significant
loss of overall protein fold. The concern is the possibility that removing part of the protein
can cause a significant change in the protein’s overall fold and this is the cause of the
reduced activity that may be observed. Average CD spectra comparing Isu1 to the D-Isu1
mutations are provided in Figure 3.2.

Table 3.1 depicts the simulation analysis

parameters determined for the secondary fold of the protein constructs. In general, a
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slight decrease in intensity of a positive feature at 190 nm and the negative feature at 208
nm in the spectrum correspond to an overall trend of loss in helical nature. Full length
Isu1 is 16.5% helical and 26.7% sheet compared to 10.3% helical and 31.0% sheet for
Isu∆22. The helical and sheet content for Isu1∆10 and Isu1∆17 truncations lie within
these values. Given that the truncations remove part of the protein’s C-terminal a-helix,
these changes follow an expected trend. In general, these truncations are consistent with
a fold representative of the active Isu1 protein in maintaining he protein’s overall general
fold, indicating an overall disruption in the protein’s structural architecture is maintained
despite changes in protein’s activity.
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Figure 3.2 Circular Dichroism comparison of Isu1 and C-terminal truncations.
Representative spectra of Isu1 (black), Isu1∆10 (blue), Isu1∆17 (red), Isu1∆22 (purple).
An average of 30 scans were collected for each representative spectrum displayed; trials
were performed in triplicate with independent samples to ensure spectral reproducibility.

92
Sample

a

b

O

D

Fit a

Isu1

16.5 ± 8.4

26.7 ± 10.5

23.8 ± 2.3

33.0 ± 0.7

0.04

Isu1∆10

12.7 ± 1.7

28.3 ± 1.7

23.9 ± 0.5

35.0 ± 0.9

0.07

Isu1∆17

15.3 ± 3.5

26.1 ± 3.4

24.5 ± 0.7

34.2 ± 0.3

0.07

Isu1∆22

10.3 ± 3.2

31.0 ± 3.2

23.4 ± 0.8

35.3 ± 1.4

0.06

Table 3.1 Circular Dichroism Simulation Parameters for wt- and mutant Isu1.
Secondary structural abbreviations include a (alpha-helix), b (beta-sheet), O (structured
other) and D (disordered).
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3.3.2 In vitro Fe binding characterization for Isu1 constructs
The iron binding stoichiometry and metal affinity for wild type Isu1 is compared to
the truncation mutations utilizing the divalent ion chelator Mag-Fura-2 to establish a
competition assay. Given that Isu1 has multiple surface exposed acidic residues (Figure
3.1) on the protein’s C-terminal helix, we hypothesized this region was likely the iron
delivery site for the protein, known to be distinct from the protein’s Cys rich active site.45,
54, 55

Previously reported Fe(II) ion binding affinities values for full length Isu1 have shown

Kd’s for 2 Fe(II) ions at 2.38. ± 0.85 and 4.55 ± 2.69 µM affinity, and these values
correspond nicely to observed for the D. melanogaster scaffold “fIscU” at 0.695 ± 242 µM
and 5.55 ± 2.54 µM when measured under competition with the chelator Mag-Fura-2.54,55
Apo Mag-Fura-2 has a well-established spectroscopic signal at 366 nm (peak maximum)
which shifts to 325 nm upon Fe(II) binding. Simulations of the 366 nm absorbance
maximum decay profile can be used to obtain protein metal-binding characteristics
(Figure 3.3). In this report, all data were collected under anaerobic conditions using. Coy
wet anaerobic chamber (Coy, Inc.) to avoid protein of Fe(II) oxidation. Simulations of
Fe(II) titration data to the Mag-Fura-2/Isu1 competition mixture indicated an optimal
binding stoichiometry of ca. 2 Fe to 1 Isu1, with relative Kd’s of 3.5 ± 1.8 and 10 ± 8.6 µM.
Surprisingly, Isu1 truncations (∆10, ∆17 and ∆22) yielded the same stoichiometry and
similar Kd’s to values measured for the wild type protein (Table 3.2). These results indicate
that the initial Fe(II) ion binding site on the protein is located at a site distinct from the
protein’s C-terminal region.
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Figure 3.3 Fe Binding Affinity to Isu1 Measured using Mag-Fura-2 within a
Competition Based Assay. Representative titration spectra of iron into Isu1 and
truncations. Mag-fura-2 to protein ratio was varied and 1:1 data is shown for Isu1 (black),
Isu1∆10 (blue), Isu1∆17 (red) and Isu1∆22 (purple). Spectra were collected in duplicate
using independent samples to ensure spectral reproducibility.
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Sample

Kd1

Kd2

Isu1WT

3.5 ± 1.8

10.4 ± 8.6

Isu1∆10

6.4 ± 0.8

15.4 ± 6.6

Isu1∆17

3.5 ± 0.7

14.6 ± 3.0

Isu1∆22

4.5 ± 1.0

7.67 ± 4.7

Table 3.2
Table of Fe(II) binding Kd’s Measured using Mag-Fura-2 in our
Competition Binding Assay. Assay was performed at 25.0 °C under anaerobic
conditions, with binding parameters determined by simulating the signal values at 366 nm
using DynaFit.110 Metal to protein stoichiometry was best fit using a 2:1 binding model.
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3.3.3 In vitro Fe binding site structural comparison for Isu1 Constructs
Given that wt-Isu1 and the truncation mutants all bound 2 eq of Fe(II) at micromolar
affinity, we utilized X-ray absorption Spectroscopy (XAS) to compare Fe(II) binding sites
between the different Isu1 constructs. Iron X-ray absorption near edge spectroscopy
(XANES) spectra for iron loaded onto the Isu1 constructs are very similar in their nature,
and pre-edge analysis indicates that the metal bound to Isu1 is Fe(II) and held in a 6
coordinate structural environment

(Figure 3.4). Analysis of the 1s→3d pre-edge

electronic transition in the Fe XANES for wt- and mutant Isu1 show features that appear
at similar peak energies, suggesting similar oxidation state for the metal in all samples,
and peak areas consistent with symmetric 6 coordinate octahedral Fe(II) geometry for the
bound metal (Figure 3.4, Table 3.3). The Fe-XANES first inflection edge energies, an
indicator for iron oxidation state, for the Isu1 samples were measured to occur at 7121.4
± 0.1, 7123.6 ± 0.2, 7123.8 ± 0.2, 7123.4 ± 0.8 for wt-, ∆10, ∆17 and ∆22 Isu1 truncation
mutants, respectively (Table 3.3). These measured values are consistent with Ferrous
ions and similar to values published for scaffold orthologs previously.54, 55 In summary,
the XANES data indicate there is no significant difference between the Fe binding sites
for all Isu1 variants investigated in this report.
Simulations of the X-ray absorption fine structure (EXAFS) region of an XAS
spectrum provides direct metrical parameters for the ligand environments of metals
coordinated to a metalloprotein. The Fourier transform (FT) of the EXAFS provides a
visualization of the pseudo radial distribution function for specific metal-ligand
coordination environments. Fe EXAFS analysis was used to characterize the metal site
structure for wt- and truncation mutants of Isu1. The Fe-EXAFS spectra for wt-Isu1 versus
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mutants, and their subsequent FT spectra, are presented in Figure 3.5. Simulations of
the Fe-EXAFS for each sample suggests iron is coordinated by oxygen and nitrogenbased ligands, with ca. 5 O/N ligands centered at an average Fe-ligand bond length of
2.19 Å and a second single distinguishable Fe-O/N environment centered at 2.01 Å. Bond
lengths from the iron nearest neighbor ligand environments in both samples are
consistent with those reported for six coordinate Fe(II)-O/N models presented within the
Cambridge Structural Database. Most significantly, sulfur scattering was not observed in
any Isu1 sample, consistent with all of our previous reports.54 The lack of sulfur scattering
in these samples indicates that the iron binding site is not changed by truncation of the
C-terminal alpha helix. In addition to the Fe-O/N nearest neighbor scattering we observe,
long-range carbon scattering is also observed in all samples at 3.01 and at 4.13 Å (Table
3.4), indicating long range structural order likely from coordinating amino acid atoms. In
combination with our competition assay studies, these data suggest that the iron binding
site is not the active site, or the C-terminal helix.
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Figure 3.4 Normalized XANES for Fe-Isu1. (A) Representative spectra for Fe XANES
for 2Fe-Isu1 (black), 2Fe-Isu1∆10 (blue), 2Fe-Isu1∆17 (red), 2Fe-Isu1∆22 (purple). (B)
Expended display of the Fe-XANES pre-edge features for 2Fe-Isu1 (black), 2Fe-Isu1∆10
(blue), 2Fe-Isu1∆17 (red), 2Fe-Isu1∆22 (purple).
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Pre-Edge Area a

Peak-First Inflection
Energy (eV)

Isu1WT

8.46 ± 2.94

7121.4 ± 0.1

Isu1∆10

5.14 ± 1.87

7123.6 ± 0.2

Isu1 ∆17

4.49 ± 1.04

7123.8 ± 0.2

Isu1 ∆22

4.20 ± 1.35

7123.4 ± 0.8

Table 3.3 Analysis of Pre-edge and Edge First-Inflection Point Features from FeXANES. Pre-edge analysis of the 1s→3d transition in Fe(II) Isu1 samples. Peak
inflection values were calculated by taking the first derivate of the edge feature for each.
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Figure 3.5 Raw EXAFS, Fourier Transforms of EXAFS and Spectral Simulations for
Fe- Isu1 and C-terminal truncations. Full Fe EXAFS for 2Fe-Isu1, 2Fe-Isu1∆10, 2FeIsu1∆17, 2Fe-Isu1∆22 are shown in (A), (C), (E), (G) respectively. Fourier transforms for
the Fe EXAFS 2Fe-Isu1, 2Fe-Isu1∆10, 2Fe-Isu1∆17, 2Fe-Isu1∆22 are shown in (B), (D),
(F), (H) respectively. Raw data is shown in black while the best-fit simulations for each
data set are shown in green.
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Nearest-Neighbor Ligand

Long-Range Ligand

Environment a

Environment a

Sample

Atom b

R(Å) c

C.N. d

s2 e

Atom b

R(Å) c

C.N. d

s2 e

F’ f

Isu1WT

O/N

2.01

1.0

3.78

C

3.01

1.5

1.14

0.99

O/N

2.14

4.5

2.94

C

4.13

3.0

4.77

O/N

2.04

1.0

4.44

C

3.51

2.0

2.35

O/N

2.16

5.0

4.91

C

4.09

2.0

3.70

O/N

2.00

1.0

1.80

C

3.19

1.0

2.41

O/N

2.15

5.0

3.31

C

4.17

2.0

3.78

O/N

2.03

1.0

1.21

C

3.51

2.0

2.79

O/N

2.16

5.0

4.60

C

4.18

2.0

1.82

Isu1∆10

Isu1∆17

Isu1∆22

0.59

0.55

0.77

a

Independent metal-ligand scattering environment.
Scattering atoms: N (nitrogen), O (oxygen), C (carbon), S (sulfur).
c
Average metal-ligand bond length (+/-) 0.12 Å-1.
d
Average metal-ligand coordination number (+/-) 1.0.
e
Average Debye-Waller factor (Å x 103).
f
Number of degrees of freedom weighted mean square deviation between data and fit.
b

Table 3.4 Summary of Isu1 truncation Fe-EXAFS Simulation Best Fit Parameters.
Spectra were fit over a k-range of 1.0 to 13.0 k-1.
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3.3.4 Cluster Assembly Activity Comparison for Isu1 and Truncation Mutants
To determine the significance of the C-terminal a-helix residues on the cluster
assembly properties of the scaffold, we utilized circular dichroism spectroscopy to monitor
the formation of 2Fe-2S clusters as a function of time within our cluster assembly
protocol.55 In these experiments, wt- and mutant Isu1 constructs were added to the NIaF
to test the effectiveness of the scaffold for accomplishing cluster assembly. Under wtIsu1 conditions, the yeast NIaU complex rapidly makes Fe-S clusters when provided with
Cys(aq) and Fe(II)aq as substrates when both reductant and Yfh1 are present in
stoichiometric amounts; cluster assembly is monitored by the increase in intensity of the
2Fe-2S specific CD signal at 430 nm.47, 55 Figure 3.6 shows the relative extent of cluster
assembly activity vs time for all Isu1 samples. When Isu1 was substituted with truncation
mutants, Fe-S cluster assembly activity was abolished. An additional scan from 700-300
nm was taken after 60 minutes to confirm or absolve overall cluster production. Full length
Isu1 shows typical cluster production after 60 minutes, consistent with our previous
reports 55, however the Isu1∆10, Isu1∆17 Isu1∆22 mutants showed no cluster production
in Figure 3.6B based on the lack of a 430 signal. These results suggest that the Isu1 Cterminus in its entirety is required for the ISC complex to complete cluster assembly.
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Figure 3.6. Fe-S cluster assembly assay. Cluster assembly assay (A) detected by
Circular Dichroism Spectroscopy at 430 nm using NIA, Yfh1, Fe(II), L-Cys, DTT and either
with apo-Isu1 (black), Isu1∆10 (blue), Isu1∆17 (red), Isu1∆22 (purple). Characteristic FeS chromophores (B) detected after Fe-S cluster assembly assay by Circular Dichroism
Spectroscopy from 700-300 nm using NIA, Yfh1, Fe(II), L-Cys, DTT and either with apoIsu1 (black), Isu1∆10 (blue), Isu1∆17 (red), Isu1∆22 (purple).
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3.4 CONCLUSION
Fe-S cluster assembly is accomplished by the coordinated activities of proteins
within the ISC assembly complex. The scaffold protein Isu1 is central to this process and
works by coordinating the delivery of iron and sulfur to be used for assembly. Despite the
importance of the pathway, Fe-S clusters are utilized in nearly every cellular pathway,
very little is known about the molecular details of Isu1, especially in the protein’s Cterminal helical region shown to be important in the disease ISCU myopathy. ISCU
myopathy results in a premature truncation of the last 10 residues of the human scaffold
protein’s C-terminus, in addition to random mutations downstream of the scaffold’s active
site (see figure 3.1). Results from this study indicate loss of the 10 C-terminal residues
in Isu1 causes a complete loss of cluster assembly activity without altering the protein’s
ability to both bind iron or causing a disruption in the protein’s bound iron site structure.
These data therefore exclude the protein’s C-terminal residues (C-terminal residues up
to A144) as likely participating in forming the proteins initial Fe binding site. Based on
recent crystallographic data of the Zn human NIaUF complex, the C-terminus of ISCU is
solvent facing and does not make direct contact with any known ISC complex proteins. It
is possible that the C-terminus of Isu1 provides a structural anchor thereby positioning
the LPPVK domain and the protein’s active site for initial coordination with partner
protein’s (i.e., frataxin, the cysteine desulfurase or to the ferrodoxin). Alternatively, this
molecular region may be required for homodimerization of the scaffold in a manner
previously reported to be important in ISCU myopathy.60 Regardless, this report shows
the C-terminus is essential for cluster assembly emphasizing a direct relationship to the
pathogenesis of ISCU myopathy.
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CHAPTER 4: DEVELOPMENT OF AN IN VIVO FRIEDREICH’S ATAXIA
MODEL USING MYOBLAST AND INSULINOMA DERIVED CELL LINES
4.0 Prelude
In my last year of graduate work, our group made an effort to add complementary
in vivo projects to the in vitro work we have done since the genesis of the Stemmler Lab.
In this section, I will describe multiple methods I optimized for working within cell culture
lines. While we were able to make some progress, much of this work is laying the
foundation for future students to build upon and the goal of this chapter is to describe the
methods in detail.

This work was generously supported by Dr. Kalyan Kondapalli,

University of Michigan, Dearborn. He provided significant insight in designing this project,
provided the laboratory resources necessary for cell culture experiments and provided
mentorship during the completion of the research. His expertise was critical, and we are
grateful for his continued support.

Ashley Pall (University of Michigan, Dearborn)

provided cell culture training and performed qPCR experiments. This work will be
continued as a joint effort between the Kondapalli and Stemmler Labs with Courtney
Campbell taking the lead (Wayne State University) in the years to come.

4.1 Introduction
Freidreich’s

ataxia

is

neurodegenerative phenotypes.

characterized

by

presentation

of

cardio

and

Patients often first present with abnormal limb

coordination around puberty.61 Neurological dysfunction progresses with age leaving
patients wheel chair bound by the second or third decade of life142 (see also chapter 1).
However, beyond changes in neurological changes, cardiovascular health is also
impaired. Most critical for survival of FA patients is the condition of the heart, as cardiac
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dysfunction is the cause of death for approximately 60% of FA patients.143 The hallmark
condition in FA is left ventricular hypertrophy and current therapeutics such as
antioxidants and iron chelators show little improvement.142

At the cellular level,

accelerated iron accumulation due to poor frataxin expression contributes to the
pathogenesis of cardiac dysfunction.144
In addition to cardiac dysfunction, FA also induces changes in pancreatic function.
Among FA patients, 10-30% develop type 2 diabetes with as many as 49% reporting with
impaired glucose tolerance145 as a result of mitochondrial dysfunction leading to
degeneration of pancreatic cells.146

However, many molecular mechanisms for the

progression of mitochondrial dysfunction to type 2 diabetes remain unclear.146
The goal of this work is to develop an in vivo phenotype for FA using myoblast and
insulinoma derived cells to further clarify frataxin’s role in the pathogenesis of the disease.
For these experiments, we chose an immortalized Rattus norvegicus myoblast line H9C2
147

for their ease of growth, availability and relevance to cardiovascular research. We also

utilized immortalized MIN6 cells 148 and INS-1 cells to investigate the molecular signaling
events leading to type 2 diabetes in FA.149

4.2 Methods
4.2.1 INS-1 Cell Culture Protocol
INS-1 cells were purchased from AddexBio (C0018007). Cells were plated on
uncoated T75 flask and grown to confluency before harvesting. Frozen cell stock were
made from initial passage cell line and stored in optimized RPMI media (AddexBio
#C0004-02) with 5% DMSO. Frozen stocks were thawed after storage at -80˚C and
tested for viability. INS-1 cells were grown in optimized RPMI media (AddexBio #C0004-
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02)

supplemented

with

10%

Fetal

Bovine

Serum

(GIBCO

#26140079),

1%Penicillin/Streptomycin (ThermoFisher 15240062) and 0.05 mM 2-mercaptoethanol
(complete media) in 6-well, T25 or T75 sterile uncoated culture flasks. Media was
replenished every 2-3 days and cells were passaged at 70% confluency approximately
every 7 days.
4.2.2 MIN-6 Cell Culture Protocol
MIN-6 cells were obtained from Jena Lab (Wayne State University). Cells were
plated on T75 flask and grown to confluency before harvesting. Frozen cell stock was
made from initial passage cell line and stored in complete DMEM media (Gibco
#26140079) with 10% DMSO. Frozen stocks were thawed after storage at -80˚C and
tested for viability. MIN-6 cells were grown in complete DMEM media (15% FBS, 1%
Penicillin/Streptomycin, 0.05 mM 2-mercaptoethanol) in 6-well, T25 or T75 sterile
uncoated culture flasks. Media was replenished every 2-3 days and cells were passaged
at 70% confluency approximately every 7 days.
4.2.3 H9C2 Cell Culture Protocol
H9C2 cells were obtained from Kondapalli Lab. Cells were plated on T75 flask and
grown to confluency before harvesting. Frozen cell stock were made from initial passage
cell line and stored in complete DMEM media (Gibco #26140079) with 10% DMSO.
Frozen stocks were thawed after storage at -80˚C and tested for viability. H9C2 cells were
grown in complete DMEM media (10% FBS, 1%Pen/Strep) in 6-well, T25 or T75 sterile
uncoated culture flasks. Media was replenished every 3-4 days and cells were passaged
at 70% confluency approximately every 7 days. H9C2 cells will undergo morphological
changes if they are overcrowded and must be split no greater than 70% confluency.
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4.2.4 General Cell Splitting Protocol
Cell splitting protocols have been described previously but restated with
clarifications.149-152 Media was aspirated and rinsed with 2-3x volume prewarmed (37°C)
sterile 1x Phosphate Buffered Saline (PBS) (ThermoFisher 10010049).

PBS was

aspirated from culture flask and prewarmed 0.25% Trypsin EDTA solution (Gibco #25200056) was added to cover surface area of culture flask (ex: 500 µL for 25 cm2 flask) and
incubated at 37˚C for approximately 5 minutes or when cells begin to detach. Cells were
observed to prevent over trypsinizing resulting in morphological changes. After
incubation, 3x volume of complete media was added to halt trypsin.

Transfer cell

suspension was transferred into a falcon tube and spun at 200xg for 5-10 minutes.
Supernatant was decanted and pellet resuspended in complete media.

Cells were

subcultured at 1:4, adjusting ratio as needed. Cells were kept in a sterile incubator
maintained at 37˚C with 5% CO2.
4.2.5 General Cell Freezing and Thawing Protocol
Cell media was aspirated and washed once in sterile, prewarmed PBS solution.
Trypsin was added as described above, incubated and halted with complete media.
Following trypsin exposure, cells were spun for 5-10 minutes at 200xg.

Media

supernatant was decanted, and cell pellet was resuspended in freezing media (complete
media with 5-10% DMSO). Aliquots of cell suspension were transferred to into cryovials
and placed in Mr. Freezy at room temperature prefilled with isopropanol and placed in 80˚C overnight. After overnight incubation in -80˚C cells were transferred to liquid
nitrogen or

-140˚C freezer storage. Following freezing protocol, one vial of recently

frozen cell stocks were thawed to test for viability and monitored for morphological
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changes using the following method. All media was prewarmed in 37˚C bath. Cells were
placed into bath and thawed until a small amount of ice is left in the cryovial, then
transferred into sterile hood. (For INS-1 cells, transfer vial directly into sterile hood and
allow pellet to thaw at room temperature). Complete media was added to cell suspension
slowly and dropwise. Cell suspension was gently mixed mix and transferred into a falcon
tube then spun down at 200xg. Supernatant was decanted to remove all DMSO then cell
pellet was resuspended in complete media, plated onto culture flask and placed in sterile
incubator.
4.2.6 Generation of frataxin knockdown model using shRNA lentivirus
A custom frataxin shRNA expression clone against human, mouse, rat
(Genecopoeia # CS-SH851L-LVRU6P, 3rd generation HIV lentiviral psi-LVRU6P vector
with U6 promoter and puromycin resistance) was packaged into a lentiviral vector by
University of Michigan Viral Vector Core. Virus was diluted 10x into confluent cells and
placed in incubator for 24 hrs.

Following incubation media was exchanged with

puromycin supplemented media (6µg/mL MIN-6, 1µg/mL H9C2, 5µg/mL INS-1) for 3-5
days. Cells were passaged and grow in puromycin supplemented media after reaching
confluency for generation of a stable knockdown cell line. Frataxin mRNA levels were
confirmed by qPCR using TaqMan gene expression assay probes (FA: 448892).
4.2.7 Atomic Absorption Spectroscopy
Cells were grown to confluency in 6-well culture flasks. Cells were washed 2x with
ice cold PBS and lysed using 100 µL RIPA buffer with protease inhibitor (Thermo) on ice
for 5 minutes. Lysate was gathered by scraping and centrifugation. Part of cell lysate was
added to 30% metal grade nitric acid for Fe analysis using graphite furnace atomic
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absorption spectroscopy (Perkin Elmer Life Sciences). Standard curves (0-10 ppb Fe)
were run prior to sample collection. Absorbance readings for Fe were taken at 248.3 nm
with 0.2 nm slits and pretreatment temperature of 1400°C.153,154 An average of five
biological replicates were done for each condition. Final values were normalized to
protein concentration by Bicinchoninic Acid Protein Assay (Pierce).
4.2.8 Cellular L-lactate measurements
Intracellular L-lactate levels were determined using L-lactate Assay kit
(CaymanChem 700510). Wild type and frataxin knockdown H9C2 cells were grown to
confluency in T75 flasks harvesting approximately 15x106 cells and lysing following
manufacturers protocol. An average of three biological replicates for each sample type
were mixed with assay reagents in duplicate in a 96 well plate. L-lactate levels were
measuring using fluorescent plate reader. Final values were normalized to protein
concentration by BCA assay and reported relative to control.

4.3 Results
4.3.1 Knockdown of FXN in model cell lines
The primary purpose of this work was to establish Friedreich’s Ataxia model cell
lines specific to primary affected tissues sites. For this reason, we developed a FA model
cell line using myoblast H9C2 and insulinoma MIN-6 cells. Both cell lines were exposed
to lentiviral packaged shRNA against frataxin to obtain protein levels consistent with
frataxin expression of FA. H9C2 FXN expression was determined by qPCR analysis and
final expression was approximately 10% of that to control cells (Figure 4.1). MIN-6 cells
were also exposed to lentiviral packaged shRNA against frataxin and protein levels were
quantitated by qPCR. Protein expression for knockdown cells is approximately 30%
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compared to the control (Figure 4.2). Stable knockdown cell lines were established from
these knockdown models for further analysis.
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Figure 4.1 Quantification of FXN expression in H9C2. Frataxin expression from qPCR
analysis of H9C2 cells transduced with shRNA (relative to control H9C2 cells), *p<0.05.
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Figure 4.2 Quantification of FXN expression in MIN6. FXN expression from qPCR
analysis of MIN6 cells transduced with shRNA (relative to control MIN6 cells), *p<0.05.
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4.3.2 Establishment of FA phenotype in model cell lines
Frataxin knockdown models in both cell lines were further analyzed for evidence
of Friedreich’s ataxia phenotype. Mitochondrial iron accumulation and perturbation in iron
homeostasis occurs in FA as a result of decreased frataxin expression.

Frataxin

knockdown cells should therefore show evidence of iron accumulation. Intracellular iron
levels for control and knockdown cells were measured by Graphite Furnace Atomic
Absorption Spectroscopy. H9C2 frataxin knockdown cells show an average increase of
cellular iron, on average 112% of control (Figure 4.3). MIN-6 frataxin knockdown cells
also show an overall increase of cellular iron on average of 156% that of control cells
(Figure 4.4). To further establish characteristic phenotypes of FA in H9C2 cells, we
measured intracellular L-lactate production, a measurement of mitochondrial oxidative
function. Cell samples with FXN knockdown expression showed increased L-lactate
production (111% to control) (Figure 4.5). Taken in combination, this provides a method
to decrease frataxin expression in critical cell lines and demonstrate evidence of
phenotypes expected in FA.
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Figure 4.3 Iron accumulation for control and FXN knockdown H9C2. Atomic
Absorption Spectroscopy for H9C2 control (light grey) and H9C2 frataxin knockdown
(dark grey). Relative intracellular iron levels were measured in triplicate with three
independent biological samples. Data is shown relative to control. Error bars represent
standard deviation, *p<0.05.
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Figure 4.4 Iron accumulation for control and FXN knockdown MIN6. MIN6 control
(light grey) and MIN6 frataxin knockdown (black). Relative intracellular iron levels were
measured in triplicate with three independent biological samples. Data is shown relative
to control. Error bars represent standard deviation, *p<0.05.
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Figure 4.5 Mitochondrial oxidative stress measured by L-Lactate in H9C2 FXN
knockdown. L-Lactate production for H9C2 control (light grey) and H9C2 frataxin
knockdown (dark grey). Intracellular lactate production was measured in triplicate with
three independent biological samples. Data is shown relative to control. Error bars
represent standard deviation, *p<0.05.
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4.4 Discussion
Friedreich’s Ataxia is hallmarked by decreased frataxin expression leading to iron
accumulation and mitochondrial dysfunction.60 Metabolically active sites, such as the
heart and pancreas, are specifically prone to damage by production of ROS leading to
cardiomyopathy and type 2 diabetes respectively.145, 155, 156,146 For this reason, we chose
to investigate myoblasts and insulinoma cell lines with frataxin deficiency. Our goal was
to first develop a FXN knockdown cell line and then determine methods to characterize
the phenotype. We were able to generate a FA model cell line using both H9C2 and MIN6 cell types. Both cell types show decreased expression of FXN consistent with levels
expressed by FA patients. However, MIN6 cell knockdown was less efficient that H9C2
despite evidence of higher iron accumulation. Iron accumulation was evident in both cell
types demonstrating an alteration in iron homeostasis.

Interestingly, MIN6 cell

knockdown was less efficient that H9C2 despite evidence of higher iron accumulation. In
addition to characteristic iron accumulation in H9C2 cells, L-lactate levels were increased
in consistent with markers for mitochondrial distress. Overall, we have provided a method
for frataxin knockdown and subsequent characterization of FA phenotype in H9C2 cells.
Insulinoma cell lines (MIN-6 and INS-1) need further optimization to demonstrate an
alteration in glucose stimulation insulin secretion function.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
5.0 Prelude
In this final chapter, I will summarize the results and conclusions from each
preceding chapter and discuss the significance of these findings to our working model of
Fe-S cluster biosynthesis. Most importantly, following the summary, I will suggest future
work to expand on my findings to answer remaining questions. This chapter is comprised
of my own writing and ideas and can be used by future lab members to continue these
projects.

5.1 Summary of Results and Future Directions
In this section I will primarily discuss the Fe-S scaffold protein, Isu1. Here I will
focus on the biophysical characterization of key regions of this protein: including the
protein’s active site, metal binding sites and structural regions responsible for cluster
assembly. I will focus heavily on the complexity of metal binding events related to Zn and
Fe loading. All of the results presented here contribute to our lab’s general working model
for the mitochondrial Fe-S synthesis pathway, a model which we are continuously
updating. Finally, I will describe specific questions and purpose future experiments to
continue this work and expand our knowledge related to Fe-S cluster biosynthesis.
5.1.1 In vitro association of Zn to Isu1
Isu1 is a complex protein that facilitates the transfer of persufide and iron and their
use for Fe-S cluster assembly. In addition to these substrates and binding the ISC protein
partners, the yeast scaffold Isu1 and its protein orthologs have been reported to bind Zn
in vitro.42, 43, 56, 57 Our data has also shown that Isu1 binds Zn in vitro at a submicromolar
affinity (Kd) with a stoichiometry of 1:1. Interestingly, Zn binding was determined by our
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XAS studies to occur at the protein’s active site. These studies also indicated that Zn and
Fe could bind at the same time and the protein’s metal binding sites were unique. A
structural investigation by circular dichroism revealed the protein becomes more
structured upon Zn loading, as reflected by an enhancement in the protein’s helical
nature.

Most significantly, Zn loaded Isu1 significantly decreases cluster assembly

activity, and this is consistent across species.56 These findings complement recent
crystallographic studies where ISCU was isolated in a Zn-bound state and Zn-loaded
protein was found in complex with NFS1 ± FXN.42, 43 Taken together, these findings
contribute to our ISC model in that they show Isu1 can coordinate both Zn and Fe (with
direct implications in the protein’s initial Fe binding site), that this binding nature is
conserved across orthologs, and that Zn binding effects overall cluster assembly likely,
possibly by reducing the protein’s inability to allow for the transfer persulfide or iron into
its active site (see figure 2.11).
One major gap in our knowledge in relation to Zn binding to Isu1 is the in vivo
significance. There is published data indicating that Zn toxicity to IscU within E. coli
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limits cell viability, and therefore these findings should be pursued with our own data using
both E. coli and mammalian cell lines. Furthermore, there is a need to investigate
changes in Zn homeostasis or Zn localization in relation to the disease Friedreich’s Ataxia
conditions. Given the similarity of Fe-S coordination sites to many Zn binding sites within
biology, it is likely that Zn toxicity could alter cluster production and activity of Fe-S cluster
proteins by binding at the same sites. Our group has both bacterial and mammalian cell
lines available to test this hypothesis.
5.1.2 In vitro association of Fe to Isu1
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In addition to Zn association to Isu1, we also explored Fe binding events in tandem
or singularly. From our data, we show that iron binds to Isu1 on O/N sites at a micromolar
affinity at a 2:1 metal protein ratio. Affinities were measured using isothermal titration
calorimetry and binding sites characterized using XAS have been well reported from
earlier studies.45, 54 We have built upon our earlier and demonstrate the highly conserved
nature of these iron binding sites indicates a similar mechanism across eukaryotes, which
was also determined by our XAS and Mossbauer studies presented in Chapter 2.
Regarding our Fe binding studies, structural analysis shows that there is little change to
the overall secondary structure of Isu1 following Fe association. Due to the lack of change
in the structure, and in conjunction with our XAS findings, it is likely that Fe binds to a site
that is predominately O/N based, and that this site is already prestructured. There are
limited O/N residues found on a structured N-terminal side of Isu1’s frataxin binding
interface (LPPVK domain and Ala loop) in the current structural data and this could be
the site that is favorable iron transfer.43

Based on our in vitro Fe binding assay

(competition assay) and XAS studies, we hypothesize that Fe binds at a site distinct from
the proteins Fe-S active site 54 and as a consequence requires subsequent transfer of the
metal once bound to Isu1 to accomplish cluster synthesis.
To date, there is no consensus on the exact Isu1 residues which coordinate Fe or
how Fe would be transferred to the active site to accomplish cluster production. Future
Isu1 mutagenesis studies will be needed to confirm or absolve possible Fe binding
residues on the protein to better solidify the protein’s mechanism of iron transfer. In
addition, isolation and characterization of Fe transfer hat may be facilitated by frataxin
binding to Isu1 would also be critical for advancing our model of Fe-S cluster assembly.
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Our previous data supports Fe loading onto Isu1 occurring through a frataxin mediated
event but the extent of these intermolecular interactions and the protein residues on Isu1
that are involved in the process remain elusive. Even recent crystallographic studies
leave the situation unclear with regards to how Fe reaches the proteins active site.42, 43, 46
Having a detailed atomic level understanding of scaffold metal loading poses therefore
on of the most significant unsolved mechanism questions in relation to characterizing FeS cluster biosynthesis and this may be key in understanding and correcting the Fe
homeostasis conditions found in Friedreich’s Ataxia.
5.1.3 Role of the Scaffold C-terminus
In this report we have also examined the highly conserved C-terminal helix region
on Isu1. Our findings using C-terminal truncation mutants demonstrate this region is
imperative for cluster assembly function. A small truncation of 10 residues from the Cterminal helix results in an inability for the protein to perform Fe-S cluster biosynthesis
when it is within the ISC complex. This 10 residue truncation is analogous in length to the
truncation found in ISCU myopathy, however the residues S141 to K155 remain
unchanged (see Figure 3.2A).

We also utilized larger Isu1 truncation mutants to

determine if iron binding was through possibly eliminating acidic residues found on this
helix (specifically residues D144, E145, D153 reported earlier by out lab as possible Fe
binding residues on the protein). Our competition assay and XAS analysis show the iron
binding activity and binding sites on Isu1 remain O/N based and that the protein binds 2
equivalents of ferrous iron despite a short to long C-terminal residue truncation. In
addition, these mutants all retained an appropriate fold, which is interesting but maybe
not surprising given these changes all occur on the isolated C-terminal alpha helix of the
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protein. From this we can infer that changes in Fe-S activity are a result of a change in
stability of binding to the ISC complex, likely driven by Isu1 C-terminal interactions with
protein partners, and these may impair frataxin binding at the Isu1-yfh1 interface. The
Isu1 C-terminus therefore plays a significant role in cluster assembly.
While we were able to determine the in vitro significance for the C-terminal helix of
Isu1, additional experiments would help us determine which molecular events are
inhibited upon protein truncation. A series of site mutations could be made to specific
residues on the C- and N-terminal sides of the active site to determine which residues are
responsible for iron delivery. The mechanism of iron transfer to Isu1 by frataxin and
subsequent transfer of Isu1 bound Fe(II) to the protein’s active site also remain an an
elusive part of the overall Fe-S reaction mechanism. Following point mutations, a series
of freeze quenched intermediates testing the transfer of iron from frataxin to Isu1 would
also be valuable. In addition to determining the iron binding residues on Isu1, we should
also explore how the Isu1 C-terminus positions the protein relative to the overall
macromolecular ISC complex. Based on the data presented in Chapter 3, it is apparent
the Isu1 C-terminus is critical for Fe-S activity. However, mechanistic details of the protein
during C-terminus remains unresolved.

Crystallographic studies show the scaffold

LPPVK domain and ala-loop on human ISCU interact with human frataxin.43
Unfortunately, these structural complexes provide only a snapshot of the interaction at
one point in time, and they do not show the entirety of the cluster assembly protein
interaction, leaving out key mechanistic details. A change in the scaffold’s C-terminal helix
could alter the ability of this region of Isu1 to be positioned correctly when it interacts with
frataxin. An equally probably scenario would be that the C-terminus, has suggested to
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be responsible for scaffold proteins dimerization that promotes an active form of the
protein, cannot form as a result of these truncations.59, 60 Both hypotheses and others
need to be tested to determine the role of the C-terminus in cluster assembly.
5.1.4 In vivo FA model
Work presented in Chapter 4 represents a new and exciting direction for our group.
We utilized multiple mammalian cell line types critical to Friedreich’s ataxia to study the
cellular consequences of altered frataxin expression. Our cardiomyoblast model, H9C2,
displayed frataxin knockdown efficiency of ca 90%.

We also have shown iron

accumulation and increased L-lactate levels in these knockdown models, all of which
would be predicted due to cell studies from other organisms related to the Friedreich’s
ataxia model systems. Using this cell line, we will further explore the mechanism of
cellular death as it relates to the iron binding activity of frataxin. Most of this work lies
within the future projects to come. Moving forward, we need to ensure the duration of the
frataxin knockdown and phenotype in relation to time. This can be tested by measuring
iron accumulation and mitochondrial function immediately after introducing the lentiviral
shRNA and then also testing relevant time intervals after selection. We could also further
develop our assessment for the FA phenotype by measuring ROS production, changes
in morphology, changes in mitochondrial function and by monitoring cell death.
Commercially produced kits are available to measure ROS production and electron
transport function within mitochondria. Iron accumulation and frataxin expression can
also be observed using microscopy. In FA, mitochondrial Fe homeostasis is perturbed,
and excess iron is pumped into the mitochondria. To mimic this state, we should also
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culture control and frataxin knockdown cells in excess iron media (Fe-Transferrin
complex) to see if this holds true in our model as well.
Once we have an advance measurement of the cellular effects of frataxin
knockdown in this cell line, we need to determine if these are related not just to frataxin
expression but to its iron binding ability. Initial experiments by our lab were completed
using yeast frataxin.44,

63, 157

Here, we will use human frataxin as it is more clinically

relevant. We will use our previous results showing the iron binding sites on yeast frataxin
and make the corresponding mutants in the human line for characterization. To make
these measurements, we need to create a series of shRNA constructs containing humanfrataxin mutants converting the site 1 (D86, E93, H95), site 2 (D101, E103) and sites 1
and 2 iron binding (pentamutant) sites to alanine. Figure 5.1 shows a sequence alignment
for human and yeast frataxin with site 1 in red and site 2 in yellow. Once we have created
the lentiviral shRNA for the site 1, site 2 and pentamutant, we can compare the
phenotypes to the control and knockdown results.
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Figure 5.1 Sequence alignment comparison between FXN and Yfh1. FXN (human)
and Yfh1 (yeast) with iron binding residues highlighted in red (site 1) and yellow (site 2).
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5.1.5 In vitro characterization of yeast and human frataxin
Critical to the studies mentioned in the above section is the utilization of humanfrataxin. Since all of our initial in vitro experiments characterizing the activity and iron
binding sites of frataxin were completed using yeast frataxin, we will need to do a full
comparison of these two constructs. These in vitro characterization studies are a strength
of our lab and can be easily completed. We already have the human and yeast frataxin
plasmids. Purification protocols are established for yeast but will need to be optimized
for the human protein. We will need to compare iron binding activity using our competition
assay for both yeast and human frataxin. The original studies on yeast frataxin were
made using ITC experiments. Given the ease of technique and in vivo like conditions
presented by our competition assay, this method would be superior for an iron binding
comparison. We will need to compare iron binding activity for the site 1, site 2 and
pentamutant frataxin constructs as well and these should all be done using the
competition assay. Structural studies comparing the secondary structure of the human
and yeast frataxin would be valuable. We need to ensure that these orthologs and
mutants, while highly similar in sequence, are also similar in fold and activity.
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ABSTRACT
THE DYNAMIC NATURE AND BIOPHYSICAL CHARACTERIZATION OF ISU1, FE-S
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Mitochondrial Fe-S cluster biosynthesis is accomplished within yeast utilizing the
biophysical characteristics of the “Isu1” scaffold protein.

As a member of a highly

homologous protein family, Isu1 has sequence conservation with orthologs and a
conserved ability to assemble [2Fe-2S] clusters.

Regardless of species, scaffold

orthologs can exist in both “disordered” and “structured” conformations and is directly
related to conformations utilized during Fe-cofactor assembly. During assembly, the
scaffold directs the delivery and the utilization of both Fe(II) and sulfide substrates in order
to produce [2Fe-2S] clusters, however Zn(II) binding can alter the activity of the scaffold
with stabilizing the protein in the structured state. Understanding the interplay between
Fe(II) and Zn(II) binding in vitro may help clarify metal loading events that occur during
Fe-S cluster assembly in vivo.
Here we determine the metal:protein stoichiometry for Isu1 Zn and Fe binding is
1:1 and 2:1, respectively. As expected, while Zn binding shifts the Isu1 to its structured
state, folding is not influenced by Fe(II) binding alone. X-ray absorption spectroscopy
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(XAS) confirms Zn(II) binds to the scaffold’s cysteine rich cluster assembly active site and
Fe(II) binds at a location distinct from the active site. XAS results show Isu1 binding of
either Fe(II) or Zn(II) does not perturb the structure of the alternatively bound metal. XAS
and Mössbauer spectroscopies combined confirm that several scaffold orthologs bind iron
as high-spin Fe(II) at a site composed of ca 6 oxygen and nitrogen only nearest neighbor
ligands. Finally, Zn binding dramatically reduces the Fe-S cluster assembly activity of
Isu1, even in the presence of frataxin. Given the metal binding activity of Isu1, a
mechanism for Fe(II) transport during cluster assembly and a possible role for Zn for the
protein have been considered in this report.
We also present evidence for the significance of the C-terminal alpha helix of Isu1.
Despite the importance of the pathway, very little is known about the molecular details of
Isu1, especially in the protein’s C-terminal helical region. Data shows that a loss of the
10 C-terminal residues in Isu1 causes a complete loss of cluster assembly activity and
impairs cellular growth without while the proteins structure and iron binding activity remain
unchanged. One possible role for the C-terminus is that it provides structural anchor
which positions the LPPVK domain and active site to make contacts with key ISC
members. This report shows the C-terminus is essential for cluster assembly emphasizing
a direct relationship to the pathogenesis of ISCU myopathy.
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